Anal fistula

Anal fistula also commonly called fistula-in-ano or perianal fistula, is a small infected tunnel that develops between the anal canal and the perianal skin (the skin near the anus where poop leaves the body) (see Figure 2) ¹. The majority of anal fistula are usually the result of an infection near the anus causing a collection of pus (abscess) near the anus or rectum ². Most anal fistulas (approximately 90% of cases) are idiopathic and are the result of an infection that starts in an anal gland (Figure 3) ³, ⁴. This infection results in an anal abscess that drains spontaneously or is drained surgically through the skin next to the anus, leaving a communicating tract between the internal anus and the external skin of the perianal region. The fistula then forms a tunnel under the skin and connects with the infected gland. Men are more commonly affected by anal fistulas than women ⁵ and the mean age of first presentation is reported to be 40 years ⁶.

The prevalence of anal fistula is reported to be approximately 1-2 per 100,00 patients in European population studies ⁷. The mean incidence of anal fistula is estimated to be 8.6 per 100,000 people, 1.04 per 10,000 people, and 2.32 per 10,000 people in Finland, Spain and Italy, respectively ⁵. However, being more than 10 years old, these reports may be outdated. A recent systematic review estimates the prevalence of anal fistula in Europe as 1.69 per 10,000 patients ⁸.

Anal fistulas are also associated with Crohn’s disease, lymphogranuloma venereum, hidradenitis suppurativa, surgery, radiotherapy and sexually transmitted diseases ⁹, as these can result in deep rectal/anal mucosal damage, which facilitates the development of fistula. Epidemiological reports on these and other relevant comorbid conditions in anal fistula are sparse. In Crohn’s disease, the cumulative incidence of anal fistula ranges between 17% and 50%, with about 35% of patients having at least one anal fistula during the course of the disease ¹⁰. Anal fistulas reported to be associated with tuberculosis are 0.2%, and 3.3% are associated with trauma ⁵. After surgery, between 1.2% of patients and 0.3% of patients develop anal fistula ¹¹, ¹². Approximately 7% of patients with lymphogranuloma venereum ¹³ and 80%-91% of patients with anorectal tuberculosis present with anal fistula ¹⁴.

Patients with chronic diseases like diabetes mellitus are also discussed to be at increased risk of anal fistula, due to their susceptibility to skin lesions and systemic infections ¹⁵ and increased risk for perianal abscesses.

Anal fistulas can cause unpleasant symptoms, such as local pain, itching, a chronic discharge of pus draining from the fistulous tract that typically has an offensive odor, which affects your daily activities and occasional bleeding and will not usually get better on their own.

Surgery is usually necessary to treat an anal fistula as they usually do not heal by themselves ¹⁶.

There are several different perianal fistula surgery procedures. The best option for you will depend on the position of your anal fistula and whether it’s a single channel or branches off in different directions. Sometimes you may need to have an initial examination of the area under general anesthetic (where you’re asleep) to help determine the best treatment.

Total sphincter preservation surgery has gradually become the first choice for anal fistula treatment ¹⁶. In the past few decades, several sphincter-sparing techniques have been established, including fistulotomy, Seton, endorectal advancement flap (ERAF), ligation of the intersphincteric fistula tract (LIFT), fibrin glue, anal fistula plug, fistula laser closure, video-assisted anal fistula treatment (VAAFT), and adipose-derived stem cells. Based on these independent sphincter-sparing techniques, to further diminish the recurrence rate, protect the anal sphincter and obtain better postoperative outcomes, some innovative, combined, and modified new therapies have been proposed and applied in clinical studies in recent years. However, due to the diversity of treatment methods and the inevitable heterogeneity of clinical trials, their variable outcomes are prone to generate confusion and misunderstanding. Your colorectal surgeon will talk to you about the options available and which one they feel is the most suitable for you. In Crohn’s disease patients, first-line treatment with anti-tumor necrosis factor α antibody is recommended ¹.

Surgery for an anal fistula is usually carried out under general anesthetic. In many cases, it’s not necessary to stay in hospital overnight afterwards.

The aim of surgery is to heal your anal fistula while avoiding damage to the anal sphincter muscles, the ring of muscles that open and close the anus, which could potentially result in loss of bowel control (bowel incontinence).

Figure 1. Rectal and anal canal anatomy

Figure 2. Anal fistula

Figure 3. Anorectal fistula

What is the recovery like from anal fistula surgery?

Pain after surgery is controlled with pain pills, fiber and bulk laxatives. Patients should plan for time at home using sitz baths and avoiding the constipation that can be associated with prescription pain medication. Discuss with your surgeon the specific care and time away from work prior to surgery to prepare yourself for post-operative care.

Can anal fistula recur?

Up to 50% of abscesses may re-present as another abscess or as a frank fistula. Despite proper treatment and apparent complete healing, fistulas can potentially recur, with recurrence rates dependent upon the particular surgical technique utilized. Should similar symptoms arise, suggesting recurrence, it is recommended that you find a colon and rectal surgeon to manage your condition.

A large meta-analysis examined risk factors for recurrence of anal fistula after fistula surgery included a high transanal fistula, horseshoe extensions, and multiple fistula tracts as well as the patient having a history of anal procedures or not identifying the internal opening of the fistula intraoperatively ¹⁷. In a study of 251 patients who had high transphincteric fistulas and were treated with loose setons history of fistula surgery, horseshoe fistula, and anterior fistula were risk factors of recurrence ¹⁸.

Types of anal fistula

Anal fistula can be short and superficial, not involving the anal sphincter (submucosal fistula) or can be long and deep, involving the just the internal anal sphincter (intersphincteric fistula) or both anal sphincters (transphincteric fistula or extrasphincteric). Most fistulae are low arising from low within the anal canal. Rarely fistulas are high, arising from above the anal canal (supralevator fistula).

Anal fistula can be divided into simple and complex types according to the degree of lesions. According to the classification standards of the American Society of Colon and Rectal Surgeons (ASCRS), simple anal fistula includes low transphincteric, and intersphincteric fistulas that cross 30% of the external sphincter. Regarding simple anal fistula, especially distal cases, fistulotomy can be used to obtain ideal treatment results ¹⁹. However, complex anal fistula is one of the refractory diseases encountered in colorectal surgery; it is transphincteric fistula that account for more than 30% of sphincter complex,. Fistulas are complex if the primary track includes high transsphincteric fistulas with or without a high blind tract, suprasphincteric and extrasphincteric fistulas, horseshoe fistulas, multiple tracks, anteriorly lying track in a female patient, and those associated with inflammatory bowel disease, radiation, malignancy, preexisting fecal incontinence or chronic diarrhea.

Simple anal fistula

Simple anal fistula are those with a single tract that involves less than 30-50% of the external anal sphincter. The preferred treatment of a simple ana fistula is to lay it open ²⁰. This is a small operation under general anesthetic, in which a probe is placed in the fistula, and the overlying skin cut to allow the tract to heal as a shallow ulcer.

Complex anal fistula

Complex anal fistula are those with multiple tracts, those that involve more than 30-50% of the external sphincter, those that involve the anterior half of the anus (in women), any fistula as a result of radiation or Crohn’s disease, and those arising in someone with already compromised sphincter function (i.e. weak anal tone prone to incontinence). These cannot simply be laid open, and often the first step is to control the sepsis by inserting a seton.

Perianal fistula classification

The Goodsall rule can help anticipate the anatomy of a perianal fistula. The Goodsall rule states that perianal fistulas with an external opening anterior to a plane passing transversely through the center of the anus will follow a straight radial course to the dentate line. Fistulas with their openings posterior to this line will follow a curved course to the posterior midline (see Figure 4). Exceptions to this rule are external openings lying more than 3 cm from the anal verge. These almost always originate as a primary or secondary tract from the posterior midline, consistent with a previous horseshoe abscess ²¹.

Figure 4. Perianal fistula Goodsall rule

Parks classification system

The classification system developed by Parks, Gordon, and Hardcastle (generally known as the Parks classification) is the one most commonly used for perianal fistula. The Parks classification categorizes perianal fistulas based on their relationship to the external and internal anal sphincters (Figures 1 and 3) ²². The Parks classification system (Figure 3 below) defines four types of perianal fistula or fistula-in-ano that result from cryptoglandular infections, as follows ²³:

• Intersphincteric
• Transsphincteric
• Suprasphincteric
• Extrasphincteric

Figure 5. Parks classification of perianal fistula

Footnote: The Parks classification of perianal fistulas illustrates a superficial fistula, intersphincteric fistula (type 1), transsphincteric fistula (type 2), suprasphincteric fistula (type 3), and extrasphincteric fistula (type 4) in relation to the internal and external anal sphincter muscles. A revised classification from the American Gastroenterological Association Technical Review Panel defines perianal fistulas as simple or complex.

[Source ²⁴ ]

Intersphincteric perianal fistula

Intersphincteric fistulas is one that crosses the internal sphincter and then has a tract to the outside of the anus. Intersphincteric fistulas are the most common type of fistula comprising 50-80% of all cryptoglandular fistulas.

An intersphincteric perianal fistula is characterized as follows:

• Intersphincteric perianal fistula is the result of a perianal abscess
• Common course – It begins at the dentate line, then tracks via the internal sphincter to the intersphincteric space between the internal and external anal sphincters, and finally terminates in the perianal skin or perineum
• Incidence – 70% of all anal fistulas
• Other possible tracts – No perineal opening; high blind tract; high tract to lower rectum or pelvis

Transsphincteric perianal fistula

Trans is a Latin word for “on the other side of.” So a trans-sphincteric fistula is one that crosses to the other side of the external sphincter before exiting in the perianal area and thus involving both the internal and external anal sphincters.

A transsphincteric perianal fistula is characterized as follows:

• In its usual variety, transsphincteric perianal fistula results from an ischiorectal fossa abscess
• Common course – It tracks from the internal opening at the dentate line via the internal and external anal sphincters into the ischiorectal fossa and then terminates in the perianal skin or perineum
• Incidence – 25% of all anal fistulas
• Other possible tracts – High tract with perineal opening; high blind tract

Suprasphincteric perianal fistula

Suprasphincteric fistula tracts travel superior to the external sphincter and cross the puborectal muscle before changing course caudal to their external opening. Accordingly, they pass the internal anal sphincter and the puborectal muscle but spare the external anal sphincter. When these patients typically present with a perirectal abscess, it may not be visible on inspection, but they will have tenderness on the digital rectal exam.

A suprasphincteric perianal fistula is characterized as follows:

• Suprasphincteric perianal fistul arises from a supralevator abscess
• Common course – It passes from the internal opening at the dentate line to the intersphincteric space, tracks superiorly to above the puborectalis, and then curves downward lateral to the external anal sphincter into the ischiorectal fossa and finally to the perianal skin or perineum
• Incidence – 5% percent of all anal fistulas
• Other possible tracts – High blind tract (ie, palpable through rectal wall above dentate line)

Extrasphincteric perianal fistula

Extrasphincteric fistulas often arise in the more proximal rectum rather than the anus and are often a complication of a procedure. Their external opening is in the perianal area and the tract courses superiorly to enter the anal canal above the dentate line.

An extrasphincteric perianal fistula is characterized as follows:

• Extrasphincteric perianal fistula may arise from foreign body penetration of the rectum with drainage through the levators, from penetrating injury to the perineum, from Crohn disease or carcinoma or its treatment, or from pelvic inflammatory disease
• Common course – It runs from the perianal skin via the ischiorectal fossa, tracking upward and through the levator ani muscles to the rectal wall, completely outside the sphincter mechanism, with or without a connection to the dentate line
• Incidence – 1% of all anal fistulas

Current procedural terminology codes classification

Current procedural terminology coding includes the following:

• Subcutaneous
• Submuscular (intersphincteric, low transsphincteric)
• Complex, recurrent (high transsphincteric, suprasphincteric and extrasphincteric, multiple tracts, recurrent)
• Second stage

Unlike the current procedural terminology coding, the Parks and colleagues classification system developed by Parks et al ²³ does not include the subcutaneous fistula. These fistulas are not of cryptoglandular origin but are usually caused by unhealed anal fissures or anorectal procedures (eg, hemorrhoidectomy or sphincterotomy).

Anal fistula signs and symptoms

Symptoms of an anal fistula can include:

• skin irritation around the anus
• a constant, throbbing pain that may be worse when you sit down, move around, poo or cough
• smelly discharge from near your anus
• passing pus or blood when you poop
• swelling and redness around your anus and a high temperature (fever) if you also have an abscess
• difficulty controlling bowel movements (bowel incontinence) in some cases

The end of the fistula might be visible as a hole in the skin near your anus, although this may be difficult for you to see yourself.

Anal fistula causes

Most anal fistulas are idiopathic (approximately 90% of cases), and is thought to originate from a blockage of the anal glands and crypts. Obstruction of the anal glands allows bacteria to proliferate and ultimately forms a perirectal or anorectal or perianal abscess. With or without surgical treatment of the anorectal abscess, there is a significant risk of fistula formation. In addition to an incision and drainage, a 5 to 10-day course of antibiotics has been shown to decrease the rate of fistula formation ²⁵.

Less common causes of anal fistulas include:

• Crohn’s disease – a long-term condition in which the digestive system becomes inflamed
• Diverticulitis – infection of the small pouches that can stick out of the side of the large intestine (colon)
• Hidradenitis suppurativa – a long-term skin condition that causes abscesses and scarring
• Infection with tuberculosis (TB) or human immunodeficiency virus (HIV). Patients with human immunodeficiency virus (HIV), with or without AIDS, are predisposed to anorectal disease and anal fistulas. These fistulas may lack internal openings and are sometimes in the absence of an underlying abscess ²⁶. In one study, fistula-in-ano accounted for 6% anorectal pathologies in HIV patients and was irrespective of the utilization of antiretroviral therapy ²⁷.
• Complication of surgery near the anus
• Sexually transmitted infections (STIs) of the anus and rectum, usually secondary to anal receptive intercourse, may predispose individuals to perianal abscess and fistula. These anorectal STIs are most commonly caused by gonorrhea, chlamydia as well as, syphilis (Treponema pallidum) and herpes simplex ²⁸.
• Radiation proctitis is another cause of anal fistulas. Radiation proctitis requires surgical intervention in less than 10% of the cases with fistula tracks to the vagina, urethra, and bladder being a common complication. Impaired microvascular healing often requires multiple treatment modalities, including local excision, flap reconstruction, and diversion of stool or urine from the site ²⁹.
• Complicated vaginal deliveries with 3rd or 4th-degree tears or requirement of episiotomy may predispose to anal fistula; however, these fistulas often heal spontaneously. In nonhealing obstetric related anal fistulas, surgical therapy is dependent on the location of the fistula as well as vaginal involvement. When distal to the dentate line, a recto-vaginal fistula becomes an ano-rectovaginal fistula. Causes include obstetrical trauma typically associated with a traumatic vaginal birth. Patients who undergo episiotomy are at increased risk for sphincter injury and fecal incontinence ³⁰.

Anal fistula results when an anal abscess bursts into the tissues surrounding the anus. This condition is common in young adults, but can occur at any age. The reason why some people develop a fistula, and others don’t is not known.

The crypto-glandular theory espoused by Eisenhammer ³¹ and Parks ³² remains the most plausible explanation for the initiating event in most cases of idiopathic anal sepsis, and is widely accepted ²⁰. This theory proposes that sepsis originates as an infection in an obstructed anal gland, usually lying in the intersphincteric space. Mitalas et al. ³³ performed histological studies on the fistula track in a series of nine patients with chronic fistula undergoing exploration of the intersphincteric space. None of the tracks contained evidence of anal gland tissue with mucin-producing cells. However, this does not disprove the theory, as it is quite plausible that glandular epithelium was obliterated during the original septic process. Whereas there has not been any recent publication confirming this theory, equally there has not been a publication proposing a more plausible explanation. Naldini et al. ³⁴ performed endoanal ultrasound scans on 175 patients with a chronic anal fissure. They demonstrated an intersphincteric fistula in 91 (53%) patients and a transsphincteric fistula in 21 (12%) patients ³⁴. The relevance of this finding is uncertain. Whilst it suggests a possible alternative cause for an anal fistula, its relevance is more likely to be an explanation for chronicity of an anal fissure ²⁰. Why some people are more prone to anal sepsis remains unexplained. Smoking and Crohn’s disease have both been shown to increase your risk of developing a fistula. The success of surgery for the treatment of fistulae due to Crohn’s disease or in the smoker is considerably lower than for other fistulas. Smoking within the last year seems to double the risk of anal sepsis, but this effect disappears 5 years after cessation of smoking ³⁵. What is less clear is the explanation for persistence of the sepsis with formation of a fistula. Infliximab infusions have been shown to increase the success of fistula closure in Crohn’s disease ³⁶.

Whilst the cryptoglandular theory assumes that an anal fistula has arisen from the spread of infection from an anal gland, the rate of fistula formation following presentation with an anal abscess is low. Two recent series have reported similar findings, with only a third of patients presenting with an abscess going on to form an anal fistula ³⁷, ³⁸. Furthermore, neither study identified any associated features that might have increased the risk of fistula formation, which was lower in diabetic patients ³⁷, ³⁸. A lower rate of 15.5% for fistula formation following an acute anal abscess has been calculated from hospital activity data ³⁹, although this only included patients undergoing surgery for an anal fistula and it is likely that the overall rate is higher as patients not seeking further medical attention would not have been captured by this data set. Why some patients go on to establish a fistula remains uncertain; possible reasons include persistent sepsis, epithelialization of the track and hormone-mediated host response ²⁰. Traditionally it has been assumed that persistence of sepsis drives fistula formation. However, earlier studies have shown a paucity of organisms in a fistula track ⁴⁰, ⁴¹ and more recent studies using molecular techniques have shown a lack of bowel-related organisms in the fistula track. Tozer et al. ⁴² used in situ hybridization to study the microflora of 18 idiopathic (cryptoglandular) fistulas. Surprisingly, bacteria were not found in close association with the luminal surface of any fistula track. Similarly, in a series of 10 patients with transsphincteric fistulas, van Onkelen et al. ⁴³ failed to identify bacteria in the fistula track using 16S rRNA sequencing in nine patients. However, immunohistochemistry revealed the presence of bacterial-derived proinflammatory peptidoglycans in all bar one fistula, with evidence of host response in 6 out of 10. This raises the possibility that fistula formation and persistence represent a host response to bacterial cell wall-derived peptidoglycans. It has been suggested (but with no evidence to confirm this) that cell wall lipopolysaccharides activate proinflammatory cytokine production, such as tumor necrosis factor α (TNFα), which could be enhanced by testosterone and inhibited by estrogen, providing an explanation for the lower incidence of anal fistulas in women ⁴⁴.

Epithelialization of the track has been hypothesized as a cause for persistence of an anal fistula, but it remains uncertain whether this is of primary etiological importance or a secondary phenomenon ²⁰. van Koperen et al. ⁴⁵ examined 18 fistula tracks and demonstrated epithelialization in 15 patients, mostly around the internal opening. However, this series only included patients with a low fistula undergoing fistulotomy. Mitalas et al. ³³ performed a similar study but on 44 patients with a higher fistula involving the external sphincter. Epithelialization of the external part of the track was observed in 11 of 44 (25%) and of the intersphincteric part of the track in 2 of 11 (22%). Thus, epithelialization is uncommon within more complex fistulas.

Another conundrum is the mechanism by which sepsis spreads around the anal canal to form fistulas of differing complexity. Whilst it is easy to envisage infection spreading along paths of least resistance, such as the intersphincteric space or circumferentially in the ischio-rectal fossas, it is more difficult to explain the spread of sepsis through the external sphincter to form a transsphincteric fistula and to provide a logical explanation as to why some fistulas involve little sphincter muscle and others involve most of the external sphincter ²⁰. A plausible explanation is that infection follows fibers of the longitudinal muscle penetrating the external sphincter, but this is by no means proven. Surgical dogma assumes that the ‘deep postanal space’ is critical to the spread of sepsis around the anus, and thus the key to eradicating a fistula was thought to be adequate drainage of this space, as well as control of the primary track. However, what constitutes the ‘deep postanal space’ is disputed, with some going as far as to question whether it exists as a distinct entity ⁴⁶, ⁴⁷. Recent radiological and anatomical studies suggest there are several potential, or actual, spaces around the anal sphincters that are likely to be important in the spread of infection. To confuse the issue further, some of these ‘spaces’ cannot be identified in the normal anal canal and only become apparent once sepsis develops and localizes to that area ⁴⁸, ⁴⁹.

Anal fistula pathophysiology

An anal fistula, which is an epithelialized connection between the anal canal and external peri-anal area, is characterized by inflammatory tissue and granulation tissue. The distal obstruction prevents the fistula from healing. Because cells are continually being turned over, there is constant debris in the fistula tract, which causes obstruction and prevents healing. The use of a seton and how it allows fistulas to heal is evidence of this as setons allow constant drainage of the fistula and usually result in the fistula migrating and healing.

Anal fistula diagnosis

See a doctor if you have persistent symptoms of an anal fistula. Your doctor will ask about your symptoms and whether you have any bowel conditions. They may also ask to examine your anus and gently insert a finger inside it (rectal examination) to check for signs of a fistula.

If your doctor thinks you might have a fistula, they can refer you to a specialist called a colorectal surgeon for further tests to confirm the diagnosis and determine the most suitable treatment.

Knowing the complete path of an anal fistula is important for effective treatment. The opening of the channel at the skin (external) generally appears as a red, inflamed area that may ooze pus and blood. This external opening is usually easily detected.

Finding the fistula opening in the anus (internal opening) is more complicated. Colorectal surgeons use the latest technology, including the following:

• Magnetic resonance imaging (MRI) is used for mapping the fistula tract and providing detailed images of the sphincter muscle and other structures of the pelvic floor.
• Endoscopic ultrasound uses high-frequency sound waves to identify the fistula, the sphincter muscles and surrounding tissues.
• Fistulography is an X-ray of the fistula after a contrast solution is injected.

Other options include:

• Fistula probe, an instrument specially designed to be inserted through a fistula
• Anoscope, a small endoscope used to view the anal canal
• Flexible sigmoidoscopy, a procedure to rule out other disorders such as ulcerative colitis and Crohn’s disease
• An injected dye solution, which may help locate the fistula opening.

Examination under anesthesia

Examination of the perineum, digital rectal examination (DRE), and anoscopy are performed after the anesthesia of choice is administered. This must be done before surgical intervention is initiated, especially if outpatient evaluation causes discomfort or has not helped to delineate the course of the fistulous process.

Several techniques have been described to help locate the course of the fistula and, more important, identify the internal opening. They include the following:

• Inject hydrogen peroxide, milk, or dilute methylene blue into the external opening and watch for egress at the dentate line; in the authors’ experience, methylene blue often obscures the field more than it helps identify the opening
• Traction (pulling or pushing) on the external opening may also cause a dimpling or protrusion of the involved crypt
• Insertion of a blunt-tip crypt probe via the external opening may help to outline the direction of the tract; if it approaches the dentate line within a few millimeters, a direct extension likely existed (care should be taken to not use excessive force and create false passages)

Anal fistula treatment

Anal fistulas usually require surgery as they rarely heal if left untreated. Treatment of anal fistula depends on the fistula’s location and complexity. The goals are to repair the anal fistula completely to prevent recurrence and to protect the sphincter muscles. Damage to these muscles can lead to fecal incontinence.

A range of treatment options include:

• Fistulotomy. The surgeon cuts the fistula’s internal opening, scrapes and flushes out the infected tissue, and then flattens the channel and stitches it in place. To treat a more complicated fistula, the surgeon may need to remove some of the channel. Fistulotomy may be done in two stages if a significant amount of sphincter muscle must be cut or if the entire channel can’t be found.
• Advancement rectal flap. The surgeon creates a flap from the rectal wall before removing the fistula’s internal opening. The flap is then used to cover the repair. This procedure can reduce the amount of sphincter muscle that is cut.
• Seton placement. The surgeon places a silk or latex string (seton) into the fistula to help drain the infection.
• Fibrin glue and collagen plug. The surgeon clears the channel and stitches shut the internal opening. Special glue made from a fibrous protein (fibrin) is then injected through the fistula’s external opening. The anal fistula tract also can be sealed with a plug of collagen protein and then closed.
• Ligation of the intersphincteric fistula tract (LIFT). LIFT is a two-stage treatment performed at Mayo Clinic’s campus in Florida for more-complex or deep fistulas. LIFT allows the surgeon to access the fistula between the sphincter muscles and avoid cutting them. A seton is first placed into the fistula tract, forcing it to widen over time. Several weeks later, the surgeon removes infected tissue and closes the internal fistula opening.

In cases of complex fistula, more-invasive procedures may be recommended, including:

• Ostomy and stoma. The surgeon creates a temporary opening in the abdomen to divert waste into a collection bag, to allow the anal area time to heal.
• Muscle flap. In very complex anal fistulas, the channel may be filled with healthy muscle tissue from the thigh, labia or buttock.

Many people do not need to stay in hospital overnight after surgery, although some may need to stay in hospital for a few days.

All the procedures for anal fistulas carries a number of benefits and risks. You can discuss this with the surgeon.

The main risks are:

• infection – this may require a course of antibiotics; severe cases may need to be treated in hospital
• recurrence of the fistula – the fistula can sometimes recur despite surgery
• fecal incontinence – this is a potential risk with most types of anal fistula treatment, although severe incontinence is rare and every effort will be made to prevent it. The word ‘incontinence’ encompasses a wide spectrum, from the odd stain in the underwear, through inadvertent passage of flatus, to frank and devastating loss of stool with the prospect of a colostomy. Incontinence has a negative impact on quality of life ⁵⁰ but so too does fistula recurrence ⁵¹ and an endless cycle of failure and recurrence is to be avoided as fecal incontinence.

The level of risk will depend on things like where your fistula is located and the specific procedure you have. Speak to your surgeon about the potential risks of the procedure they recommend.

Risk factors for fecal incontinence after fistula surgery include a history of anorectal procedures, female gender, complex fistulas, and preoperative incontinence. Fistulotomy should be avoided in fistulas, which are grades 3 or 4 as complex fistulas are associated with higher rates of postoperative incontinence ⁵². Performing anal manometry can be helpful preoperatively in determining which patients should undergo a sphincter sparing approach as patients that exhibit signs of incontinence before surgery are more likely to have worsened function postoperatively ⁵³. A history of incisions and drainage or multiple fistula surgery is associated with a higher risk of worsened postoperative sphincter function as well as the type of operation performed, a fistulotomy, or a sphincter sparing procedures ⁵⁴.

Female sex is a risk factor for postoperative incontinence. Treatment of incontinence to flatus and stool involves biofeedback therapy, sacral nerve stimulation. A systematic approach to fecal incontinence has been proposed with initial treatment consisting of bulking agents for stool and increasing dietary fiber followed by training of the pelvic floor muscles with biofeedback therapy. If these are not effective, then more invasive options, including surgical sphincteroplasty, magnetic anal sphincter, or implantation of an artificial anal sphincter may be considered. Only in patients that have exhausted all non-invasive and invasive options is a colostomy offered for recalcitrant fecal incontinence ⁵⁵.

The best remedy for any complication is prevention. One way to prevent incontinence is by minimizing the number of procedures a patient requires for his or her fistula and tailoring therapy for high-risk patients. Counseling patients preoperatively on the risks of fecal incontinence and obtained preoperative anal manometry are all useful for stratifying patients preoperatively. Obtaining preoperative imaging to classify fistulas before surgery more accurately should be considered as well.

Fistulotomy

A fistulotomy is a procedure that involves cutting open the whole length of the fistula, scraping and flushing out the infected tissue, and then flattening the channel and stitches it in place so it heals into a flat scar. A fistulotomy is the most effective treatment for many anal fistulas, although it’s usually only suitable for fistulas that do not pass through much of the sphincter muscles, as the risk of bowel incontinence is lowest in these cases.

Fistulotomy has an extremely high (95%+) cure rate, as long as all tracks are dealt with ⁵⁶, ⁵⁷. As a general rule, fistulotomy results in a reliable cure with good patient satisfaction, where 2 cm of proximal muscle remains intact and in the presence of a ‘normal’ bowel habit, without urgency and in the absence of irritable bowel symptoms ²⁰.

If the surgeon has to cut a small portion of anal sphincter muscle during the procedure, they’ll make every attempt to reduce the risk of bowel incontinence.

In cases where the risk of incontinence is considered too high, another procedure may be recommended instead.

Marsupialization

Marsupialization is the surgical technique of cutting a slit into an abscess or cyst and suturing the edges of the slit to form a continuous surface from the exterior surface to the interior surface of the cyst or abscess. Sutured in this fashion, the site remains open and can drain freely. This technique is used to treat a cyst or abscess when a single draining would not be effective and complete removal of the surrounding structure would not be desirable. Marsupialization after fistulotomy is associated with a significantly shorter healing time and a shorter duration of wound discharge ²⁰. Four randomized trials have demonstrated that marsupialization of the fistulotomy wound reduces time to wound healing ⁵⁸, ⁵⁹, ⁶⁰, ⁶¹. Ho et al. ⁵⁹ demonstrated a faster healing time (6 vs 10 weeks) in 103 patients randomized to fistulotomy vs fistulotomy with marsupialization. A higher squeeze pressure was also seen in the marsupialized group, but the clinical relevance of this is unclear. Pescatori et al. ⁶¹ studied 46 patients in the same way and found less bleeding as well as a quicker reduction in wound size in the marsupialized group. More recently, Jain et al. ⁶⁰ randomized 40 patients to fistulectomy or fistulotomy with marsupialization, demonstrating faster wound healing (around 5 weeks vs around 7) and earlier cessation of wound discharge. Chalya et al. ⁵⁸ found similar results in 162 patients randomized between the same procedures.

Seton placement

If your fistula passes through a significant portion of anal sphincter muscle, your surgeon may initially recommend inserting a seton. A seton is a piece of surgical thread that’s left in the fistula for several weeks to keep it open. This allows it to drain and helps it heal, while avoiding the need to cut the sphincter muscles.

Essentially a seton can be used in three main ways in the treatment of an anal fistula, with myriad variations of technique between published series. The seton can be inserted and tied loosely over the sphincter to drain the track and allow sepsis to settle before it is removed, in the hope that the fistula will heal (loose seton). The seton can be used to divide the sphincter muscle slowly to eradicate the fistula (cutting seton) and the seton can be used as a long-term drain to provide palliation of symptoms from the fistula, where other techniques are deemed unsuitable.

Loose setons allow fistulas to drain, but do not cure them. To cure a fistula, tighter setons may be used to cut through the fistula slowly. This may require several procedures that the surgeon can discuss with you. Or they may suggest carrying out several fistulotomy procedures, carefully opening up a small section of the fistula each time, or a different treatment.

Loose seton

A loose seton can be used to treat ‘high’ and complex anal fistulas with low risk to diminishing anal control. A loose seton, used as sole treatment, results in fistula healing in only a small proportion of patients. Higher healing rates are achieved by staged fistulotomy after a period of seton drainage.

A number of series of patients treated with a loose seton continue to be reported, often with subtle variation in technique and all highlighting the relative safety of this technique as regards alteration in anal control. However, convincing evidence of fistula healing following simple removal of a loose seton is scant, and often an additional procedure is required to achieve fistula healing. Galis-Rozen et al. ⁶² reported a series of 77 patients, 17 of whom had Crohn’s disease and were treated with a loose seton alone. Of the 60 patients with non-Crohn’s fistulas, only 4 healed without further surgery and 20 (46%) healed following second-stage fistulotomy. However, a similar proportion of patients either had recurrence or did not heal following seton placement, possibly reflecting the complexity of fistulas included in this series. In a similar manner, Lim et al. ⁶³ described an intriguing modification of the loose seton technique. The primary track was re-routed into the intersphincteric space, by dividing the mucosa and internal sphincter below the internal opening and placing a seton around the external sphincter in the intersphincteric plane, before closing the internal opening, mucosa and divided internal sphincter over the seton. Fifty-three patients were treated by this technique, with a reported recurrence rate of 13% and incontinence reported by two patients. However, follow-up was mostly by telephone contact and no clinical assessment was made to confirm healing of the fistula. An alternative approach was reported by Pinedo et al. ⁶⁴ in 18 patients with transsphincteric fistulas. The external part of the track was laid open to the outer surface of the external sphincter and an internal sphincterotomy was performed to lay open the intersphincteric element of the track. A loose elastic seton was inserted in the remaining track through the external sphincter and removed when the internal opening had migrated to the anal verge. All setons were eventually removed after a median of 4 months; however, it is not clear how many fistulas healed, although there was deterioration in anal control reported. Subhas et al. ⁶⁵ used a silk seton as a loose seton, which the patient was instructed to rotate through 360° in each direction on a daily basis. Twenty-four patients were followed for a mean of 45 months (but only by questionnaire and telephone interview), with 18 (75%) fistulas healing, 9 once the seton extruded spontaneously and 9 after low fistulotomy of the residual track: two patients developed incontinence of liquid stool only. Kelly et al. ⁶⁶ followed a series of 200 patients treated with a polybutylate (Ethibond™) suture, with a recurrence rate of 6% and a low rate of incontinence. However, follow-up was short (6 months) and detail of how changes in anal control were defined and assessed was lacking. Furthermore, although the loose seton controlled symptoms, most patients ended up requiring a second procedure to lay open the residual fistula track. Follow-up is not described in any detail and four patients (6%) were said to have experienced ‘minor’ incontinence.

Tight seton (cutting seton)

A tight seton can be used to treat selected ‘high’ and complex anal fistulas where other techniques are either not suitable or have failed. The patient should be counselled carefully as to the risk of permanent incontinence. A tight seton inserted into a transsphincteric fistula will result in healing in upwards of 90% of patients. There is some risk of diminishing anal control that is influenced by the height of the internal opening and the amount of muscle encompassed in the seton.

A tight seton has been used where a surgeon is unwilling to perform fistulotomy because it is thought that too much sphincter will be divided in the process and the risk of incontinence is high. A variety of techniques have been described, all with the same principle, namely slow division of the sphincter encompassed by the seton, with progressive caudal migration of the track and eventual extrusion of the seton. Much is made of the theory that this slow division with a foreign material generates fibrosis around the sphincter as it is divided, limiting separation of the sphincter ends and healing of the muscle cephalad to the seton as it descends the anal canal. This is in contrast to the springing open of the sphincter ends that occurs with primary fistulotomy. Attractive as this theory sounds, there is little or no evidence to substantiate improved sphincter morphology and function over immediate fistulotomy. Anecdotal comparison of ultrasound appearances of the sphincters after cutting seton suggest less sphincter separation than after fistulotomy, but it is uncertain if like is being compared with like ⁶⁷. Rosen and Kaiser ⁶⁸ used data from Ritchie et al. ⁶⁹ to demonstrate an association between the rate of incontinence and the interval between seton tightening, which they interpreted as supporting evidence that slow sphincter division preserves sphincter function. However, this requires a large leap of faith, as the data used were very heterogeneous, with different definitions of incontinence and periods of follow-up.

Evidence in favor of the use of a cutting seton is still based on case series, and no specific randomized trial of tight setons vs other surgical options has been performed. Most studies suffer from a number of flaws, usually involving the definition of end-points, limited follow-up and low numbers. A variety of different materials have been used as tight setons, including silk ⁷⁰, rubber bands, rubber surgical glove ⁷¹, silastic vessel sloop ⁷² and electrical cable tie ⁷³. Each modification is designed to make tightening the seton simple as well as avoiding the need for a general anaesthetic. Similarly, some authors perform internal sphincterotomy prior to seton insertion ⁷⁴ and others encompass both the external and internal sphincters in the seton, after removing skin and anoderm beneath the seton ⁶⁷. Whichever technique is employed, the internal sphincter will eventually be divided by the seton as it cuts through the fistula track and overlying sphincter. Vial et al. ⁷⁵ performed a meta-analysis on a number of case series looking at recurrence rates and alteration in anal control after use of a cutting seton, with and without sphincterotomy at time of seton insertion. They concluded that recurrence rates were similar (at less than 5%), but overall incontinence was higher after sphincterotomy (25%) than after seton insertion without sphincterotomy (6%). However, these results should be interpreted with considerable caution as the studies were very heterogeneous, with different follow-up periods and different methods of assessing changes to incontinence.

Raslan et al. ⁷⁰ collated 51 patients treated with a tight silk seton, with a recurrence rate of 10% and incontinence to flatus of 16% and liquid stool of 6%. However, details as to the anatomy of the fistulas treated and how continence was assessed are absent and follow-up duration was not specified, but was likely to have been short. A similar study by Kamrava et al. ⁷⁶ used silk, but tightening of the seton was controlled by the patient. Recurrence was 10% and only 1 of 47 patients was reported to have new problems with control, although definitions used for assessing control were loose and follow-up was short. Using a thin electrical cable tie as a seton is intriguing: Memon et al. ⁷³ reported a series of 79 patients with transsphincteric or suprasphincteric fistulas, with a recurrence rate of 5% and no reported change in continence. However, no details were given as to the level of discomfort experienced by the patients, who required on average six tightenings of the seton and an average of 12 weeks for healing to occur. Hammond et al. ⁷² used a silastic vessel and nerve sloop as a ‘snug’ seton in a series of 29 patients. The seton cut through the enclosed tissue in 15 patients, but 14 patients required a superficial fistulotomy to finally remove the seton. There were no recurrences identified, and 10 patients (34%) experienced early minor incontinence, which persisted in 4 of 16 patients followed for a median of 42 months. Leventoglu et al. ⁷¹ used a rubber glove as a ‘hybrid’ seton; this was not tied as tightly as a traditional cutting seton with the same intention as Hammond et al. ⁷². Side tracks were dealt with by a modified Hanley technique, using Penrose drains. With this technique there was one recurrence over a mean follow-up of 20 months and no significant change in the Cleveland continence score. Ege et al. ⁶⁷ used the cuff from a rubber glove as a ‘hybrid’ seton, tied snugly over the denuded external sphincter following internal sphincterotomy. They followed 128 patients, with the seton extruding after a mean of 19 days, suggesting that many fistulas were low. Complete healing occurred at 3 months in all patients and only two patients returned with a recurrent fistula after a minimum of 12 months’ follow-up. However, in common with other studies, it is unclear as to how tightly the seton was tied over the sphincter. Izadpanah et al. ⁷⁴ described a technique they called a ‘pulling seton’ in a large series of 201 patients in whom they divided the internal sphincter and the external part of the fistula, before tying a seton over the remaining external sphincter muscle. The patient was instructed to tug on the seton four times a day. Using this technique, they reported a recurrence rate of 5% and no permanent gas or faecal incontinence. However, follow-up was short and postoperative assessment of continence was limited. Rosen and Kaiser ⁶⁸ reported on 121 patients with a transsphincteric fistula treated by tight seton. Initial healing occurred in 90% of patients, rising to 98% after further surgical procedures. Interestingly, 17 patients with preexisting continence problems improved following surgery, indicating that the presence of a fistula can cause continence problems (possibly by discharge through the track). Only eight patients developed new problems with anal control. These excellent results should be interpreted with some caution as follow-up of these patients was short (mean 5 months).

In summary, a variety of materials have been used as a cutting seton, with most series reporting successful healing of the fistula and recurrence rates of the order of 10% after short-term follow-up. It is uncertain if internal sphincterotomy is a necessary part of the procedure. It is likely that sphincter division (even slow division) will inevitably lead to some diminution in anal control, which may not become apparent immediately. Ritchie et al. ⁶⁹ collated a large number of series and calculated an average incontinence rate of the order of 12%.

Advancement flap procedure

An advancement flap procedure may be considered if your fistula passes through the anal sphincter muscles and having a fistulotomy carries a high risk of causing bowel incontinence. An advancement flap may also be used to close an anorectal or recto-urethral fistula.

Advancement flap surgery involves cutting or scraping out the fistula and covering the hole where it entered the bowel with a flap of tissue taken from inside the rectum, which is the final part of the bowel.

An advancement flap procedure has a lower success rate than a fistulotomy, but avoids the need to cut the anal sphincter muscles.

Adequate vascularity of the flap and tension-free anastomosis, placed well beyond the site of the (excised) internal opening, are key to success. Advancement flaps can be taken from the rectum (transanal advancement flap) or from the perianal skin (cutaneous advancement flap). Also described are the transanal sleeve advancement flap (TSAF) and the Delorme’s-style advancement flap. This is similar to the transanal sleeve advancement flap (TSAF) but, as in the Delorme’s procedure for rectal prolapse, after mucosal mobilization the muscle wall is advanced and sutured down to the internal anal sphincter distal to the internal opening of the fistula. This procedure is facilitated by internal intussusception and would not be a tension-free repair without it ⁷⁷. The presence of internal intussusception or perineal descent may facilitate advancement flap repair.

A number of factors have been identified as risk factors for failure of an advancement flap procedure. These include, smoking ⁷⁸, a flap for a recurrent fistula ⁷⁹, Crohn’s disease ⁸⁰, horseshoe abscess ⁸¹ and high BMI ⁸². Differing study populations may explain heterogeneity in the significance of risk factors identified in different studies.

Advancement flap procedures are safe. Early case series suggested efficacy in around 70% of patients ²⁰. However, more recent randomized controlled trial data, often vs the anal fistula plug, and larger series, suggest healing in a smaller proportion, perhaps of the order of 50–60% ⁸³, ⁸⁴. A recent multicentre randomized trial of 94 patients from Scandinavia found a primary success rate (defined as clinical healing), at a median of 12 months of follow-up, of 62% of 40 patients ⁸⁵. A full-thickness flap was used and patients had a single, non-complex high transsphincteric track and after only a single previous fistula operation (probably seton insertion). The comparator group, treated with a fistula plug, achieved clinical success in only a third of patients. MRI confirmation of healing was not reported in either arm ⁸⁵. This study represents a robustly performed assessment of transanal rectal advancement flap surgery in well-selected patients, and is a realistic report of the technique ⁸⁵. A recent meta-analysis including 26 studies and 1655 patients indicated an increasing success rate (avoidance of recurrence) with increasing thickness of the flap raised, although there was significant heterogeneity between studies ⁸⁶. The pooled recurrence rate was 21%, but ranged from 0% to 47%. Core out vs curettage of the track did not influence outcome.

There is great heterogeneity in how continence is assessed following advancement flap surgery. Early studies found little impairment of continence but some authors suggest minor incontinence may occur in around a quarter of patients ⁸⁷. Meta-analysis suggests a greater likelihood of continence impairment with full-thickness flaps (20%) than mucosal or partial thickness flaps (10%), although the impairment was generally minor ⁸⁶.

Transanal advancement flap

Transanal advancement flap can be used to treat an anal fistula where simple fistulotomy is thought likely to result in unacceptable impairment of continence. The success rate of transanal advancement flap is of the order of 60%.

The transanal rectal advancement flap procedure has several advantages over other treatments for anal fistula. Division of the external sphincter is avoided with less risk of impairment of continence, and defects of the contour of the anal canal, such as a keyhole deformity, are avoided and healing is quicker than after fistulotomy. Additional procedures can be incorporated into the operation, such as sphincteroplasty, without the need for a protective colostomy. Failure of the repair does not usually lead to worse symptoms, although the internal sphincter at the level of the anorectal junction will have been disrupted to a certain extent and the anal canal will be somewhat more rigid as a result of scar tissue. This could result in functional impairment.

Relative contraindications to the transanal rectal advancement flap procedure include: the presence of proctitis – especially in patients with Crohn’s disease; undrained sepsis and⁄or persisting secondary tracks; an anorectal fistula with a diameter > 3 cm; malignant or radiation-related fistula; a fistula of less than 4 weeks’ duration; and an associated stricture of the anorectum ⁸⁸. Stricture, tissue loss and scarring of the anorectum may impair the surgeon’s access and may make flap repair technically impossible.

The surgical technique for endoanal advancement flap procedures has been described in earlier publications ⁸⁹, ⁹⁰, ⁹¹. Whilst many surgeons would use mechanical bowel preparation prior to surgery, and consider the use of a defunctioning stoma to cover the procedure, there is no evidence base to support these approaches. A semi-circular flap is most commonly used as this avoids ischemia at the corners. The majority of authors describe a U-shaped flap, while a minority use an inverted U-shaped flap. The flap consists of mucosa, submucosa and a varying degree of circular muscle from none to the full rectal wall thickness, depending on the author. There has been limited evidence from individual studies to support the logical assertion that more muscle means greater vascularity and therefore success, at the cost of a greater risk of impairment of continence, but pooled data from a recent meta-analysis suggest that this is correct ⁸⁶.

Transanal sleeve advancement flap (TSAF)

The transanal sleeve advancement flap (TSAF) procedure takes the concept of flap advancement one step further by mobilizing the circumference of the anal canal. It has been used for a subgroup of patients with severe complex fistulas associated with Crohn’s disease ⁹². The technique is similar to the transanal flap procedure described above, but in addition a 90–100% circumferential incision is made at or just below the dentate line to create a sleeve of the full thickness of the bowel wall. This is then mobilized proximally into the supralevator space until sufficient mobility is achieved to allow the flap to be advanced distally into the anal canal without tension. Its distal edge is then sutured with absorbable sutures to the epithelium of the anal canal below the level of the internal opening. This technique may offer an alternative in selected patients with fistulation in Crohn’s disease without proctitis, for whom the only alternative is proctectomy with permanent stoma.

The cutaneous advancement flap procedure

The cutaneous advancement flap procedure is an alternative to rectal advancement flap repair of a high fistula. The cutaneous advancement flap procedure has a similar success rate to endoanal flap, but the theoretical risk of avoiding ectropion formation.

The cutaneous advancement flap appears to have a similar success rate to endoanal flap procedures, with the theoretical advantage that by moving skin into the anal canal, mucosal ectropion is avoided ⁹³, ⁹⁴. The technique for the procedure has been described elsewhere ⁹³, ⁹⁴.

Ligation of the intersphincteric fistula tract (LIFT) procedure

The ligation of the intersphincteric fistula tract (LIFT) procedure is a treatment for fistulas that pass through the anal sphincter muscles, where a fistulotomy would be too risky. During the treatment, a cut is made in the skin above the fistula and the sphincter muscles are moved apart. The fistula is then sealed at both ends and cut open so it lies flat.

This procedure has had some promising results so far, but it’s only been around since 2007 ⁹⁵, so more research is needed to determine how well it works in the short and long term.

Three randomized controlled trials have been reported ligation of the intersphincteric fistula tract (LIFT) procedure ⁹⁶, ⁹⁷, ⁹⁸. One only compared LIFT with a modification of LIFT, rather than a standard treatment, whilst the other two compared LIFT with a mucosal advancement flap. In addition, 18 case series have been reviewed ²⁰.

Madbouly et al. ⁹⁸ randomized 70 patients to either LIFT or a mucosal advancement flap. Primary healing was achieved in 33 (94%) patients undergoing LIFT compared with 32 (91%) patients undergoing a flap repair. Median healing times were 22.6 and 32.1 days, respectively. After follow-up of 1 year, a successful outcome was achieved in 26 (74%) of the LIFT group compared with 20 (66%) in the advancement flap group, highlighting the importance of long-term follow up in fistula surgery research. There was no significant difference in continence scores in this study.

A similar, but smaller, study randomized 25 patients to LIFT and 14 to anorectal advancement flap ⁹⁶. All patients had seton inserted prior to definitive surgery. Recurrences were seen in 2/25 and 1/14, respectively. The authors concluded that LIFT was simple and safe, took significantly less time than a flap and patients returned to work earlier.

Sileri et al. ⁹⁹ reported 26 patients with complex fistulas, 19 of whom were healed at a minimum of 16 months following LIFT. The recurrences occurred between 4 and 8 weeks following surgery. They defined ‘complex’ as any track that was deeper than 30% of the external sphincter, anterior fistula in women, recurrent fistula or preexisting incontinence. Only two patients had previously had a loose seton inserted prior to the LIFT procedure. Another series of 40 patients with transsphincteric fistulas deemed to be inappropriate for fistulotomy underwent LIFT ¹⁰⁰. Success rates of up to 74% were noted, although follow-up was short (a mean of 18 weeks).

Ooi et al. ¹⁰¹ reported 25 patients who had undergone LIFT. Ten of them had developed recurrence after previous fistula surgery. The primary and secondary end-points were cure rate and degree of incontinence, respectively. Primary healing was observed in 17 (68%) patients at a median of 6 weeks. Seven patients had recurrence of their fistula, which presented between 7 and 20 weeks’ postoperatively. There was no reported incontinence. Liu et al. ¹⁰² recruited 38 patients between 2008 and 2011. At a median follow-up of 26 months (26 patients had at least 12 months’ follow-up), healing was seen in 23/38 (61%). One failure occurred over 12 months after the index procedure, with 80% of failures occurring within the first 6 months following the procedure. No intra-operative complications or incontinence were noted. Increasing fistula length was associated with decreased likelihood of healing.

A recent large series (167 patients) reported a success rate (healing) of 94% at a median follow-up of 12 months ¹⁰³. The majority of fistulas were transsphincteric ¹⁰⁴ and a number were recurrent ¹⁰⁵. Ten patients who developed a recurrent fistula were managed with a repeat LIFT procedure. Schulze et al. ¹⁰⁶ performed LIFT on 75 patients between May 2008 and June 2013. All had undergone an initial procedure that involved drainage of sepsis, insertion of a loose seton and partial fistulotomy. There were nine recurrences, at a mean follow-up of 14.6 months, all of which were treated with repeat LIFT and biograft or anorectal advancement flap. There were no subsequent recurrences. Recurrences were related to fistulas with multiple tracks. Only one patient reported a change in continence.

An attempt has been made to determine whether LIFT is more effective in distinct fistula sub-types ¹⁰⁷. LIFT was performed in simple transsphincteric (five), complex fistulae (six) and recurrent cases postfistulotomy (six). The overall success rate at a mean follow-up of 11 months was 53%. Healing rates in the three groups were four out of five, three out of six and two out of six, respectively. These numbers are too small to draw any conclusions, but intuitively LIFT should be more likely to succeed in less complicated fistulas (as is the case for all fistula treatments). There is general consensus that the presence of multiple tracks, diabetes mellitus, perianal collections and long tracks are all associated with a higher chance of failure of LIFT.

LIFT has been employed as an alternative to fistulotomy in patients with low transsphincteric fistulas ¹⁰⁸. Healing was seen in 18/22 patients recruited at a median follow-up of 19.5 months. The four unsuccessful cases were treated with fistulotomy. Although there was no comparison with patients with similar fistulas undergoing fistulotomy as sole treatment, the authors reported a final healing rate of 100% and no alteration in continence, which was assessed prospectively.

A Chinese group recently reported on 43 patients with ‘complex’ fistulas treated by LIFT, all of whom were followed up for more than 1 year ¹⁰⁹. Healing of the fistula was seen in 36 of 43 (84%) patients; failure, when seen, occurred a mean of 8.6 weeks after the original procedure. In this series, eight patients had dehiscence or infection at the site of the intersphincteric wound, with five patients requiring laying open. This complication is probably commoner than reported in many series.

Modifications to the LIFT procedure have been described. The Bio-LIFT procedure, for example, involves placing a biograft (usually a piece of collagen mesh) in the intersphincteric space following ligation of the intersphincteric fistula track. Success was reported in 11 of 16 (63%) fistulas treated, at a median follow-up of 26 weeks ¹¹⁰. A randomized trial comparing the two approaches in 235 patients reported healing rates at 6 months of 94% in the LIFT + biograft group, vs 84% in the LIFT group alone ⁹⁷. The authors reported that the addition of the graft had the advantage of higher healing rates, decreased healing time and a lower early postoperative pain score. Another modification involves making a lateral incision from the external opening to the intersphincteric groove, ligating the fistula track within the intersphincteric space and complete excision of the external part of the fistula ¹¹¹. In a series of 39 patients treated in this way and followed for a mean of 15 months, 34 (87%) achieved healing. There was no change in continence, as measured by the Cleveland Clinic score preoperatively and at 6 months postoperatively. An alternative approach is to de-roof the fistula from internal opening to intersphincteric groove and ligate the fistula track, while at the same time preserving the external sphincter. This modified LIFT was performed on a series 56 patients, with an overall cure rate of 71%. True recurrence (5%) was much less frequent than simple failure of the technique and persistence of an active fistula track after the operation ¹¹².

LIFT has been used as treatment for recurrent fistulas ¹¹³. Fifteen patients with recurrent transsphincteric fistulas were followed up for 8–26 months (median 13.5 months). At the end of follow-up, six patients still had evidence of fistula, either persistence of the original fistula (four patients) or recurrence (two patients). LIFT has also been used in selected patients with Crohn’s disease, with 8 of 12 reported to be healed at 12 months ¹¹⁴.

To conclude, to date there are a few randomized studies as well as number of case series that attest to the potential efficacy of LIFT. LIFT appears to be associated with less functional compromise than some traditional treatments of transsphincteric fistulas, although recurrence/persistence rates are probably similar. One of the advantages of the LIFT procedure is that of secondary success. Where a genuine downstaging of the fistula from transsphincteric to intersphincteric takes place in a proportion of failures, allowing laying open of this intersphincteric fistula, preserving the external sphincter which would have been involved originally ¹¹⁵. Future work should focus on comparison with standard treatments, paying particular attention to comparing similar fistulas and focusing on deeper fistulas, where conventional treatments may be more problematic as regards functional outcome.

Fibrin glue

Treatment with fibrin glue is currently the only non-surgical option for anal fistulas. It involves the surgeon injecting a glue into the fistula while you’re under a general anesthetic. The glue helps seal the fistula and encourages it to heal.

It remains uncertain as to which fistulas are suitable for fibrin glue treatment. Success (fistula healing) is low when the fistula track is short. Treatment with fibrin glue is generally less effective than fistulotomy for simple fistulas and the results may not be long-lasting, but it may be a useful option for fistulas that pass through the anal sphincter muscles because they do not need to be cut.

With variable and mostly low rates of healing, fibrin glue is not recommended for routine use in anal fistulas, but may be considered where other surgical options are not feasible ²⁰.

Various autologous and commercial preparations of fibrin glue have been used to treat anal fistulas. Autologous glues are formed from the patient’s own blood, whilst commercially available glues are a mixture of clotting factors, aprotinin and calcium (Beriplast; CSL Behring, Pennsylvania, USA; Tisseel; Baxter Healthcare, Deerfield, Illinois, USA), or are synthetic glues, such as cyanoacrylate (Glubran; GEM SRL, Viareggio, Italy). The glues are applied to fill the fistula track and provide a bridge for fibroblasts and stromo-vascular cell in-growth to produce healing. Their ease of use, minimal risk to continence and repeatability make them an attractive option, especially in patients at high risk of sphincter dysfunction ¹⁰⁴, ¹¹⁶.

A wide range of healing rates with fibrin glues have been reported, ranging from 14% to 94% ¹¹⁷, ¹¹⁸. Variability in disease complexity, fistula anatomy and surgical technique makes comparison of the results from randomized trials difficult to interpret ¹¹⁹. A meta-analysis has not shown any statistical difference with the use of fibrin glue, compared to other conventional surgical treatments, in terms of fistula recurrence or incontinence ¹²⁰.

Some authors have reported better healing rates in longer tracks, suggesting that shorter tracks (< 3.5 cm) are less likely to retain the glue ¹²¹, but this has been contradicted in other reports ¹²², ¹²³. Technical errors have been suggested for failure, including inadequate curettage and washout to remove all infected and epithelialized tissue 155, 161, 162, or incomplete filling of the track with the glue to ensure occlusion ¹²¹.

Like other fistula treatments, recurrence rates with fibrin glue increase with the length of follow-up. A long-term follow-up study showed that up to 26% of patients who were symptom free at 6 months went on to develop recurrence at an average of 4.1 years ¹²⁴. However, on several occasions the recurrence was at a different site, suggesting that a new fistula had formed. The highest probability of failure appears to occur in the first 6 months following treatment, so 6 months should be the minimum follow up period ¹²⁵.

A multicentre trial randomized patients to fibrin glue or seton treatment for transsphincteric fistulas and showed a 38% healing rate in the fibrin glue group, compared with 87% in the seton group ¹⁰⁴. Patients who had a recurrence after fibrin glue were further randomized to repeat glue treatment or a loose seton. A further 50% healed with repeat glue treatment. Notably, there was a significant worsening in the Cleveland Clinic continence score in the seton group. Many studies have investigated the use of repeat glue application to increase healing rates, even up to four applications ¹²⁶. A prospective study of fibrin glue for simple transsphincteric and intersphincteric fistulas showed that repeat glue treatment decreased the overall recurrence rate from 23% to 7.6% ¹²⁷. Conversely, other authors have reported that repeated applications of fibrin glue are unlikely to succeed ¹²⁸ and other studies have shown an adverse outcome when fibrin glue is combined with an endorectal advancement flap ¹²⁹.

Various strategies have been suggested to improve the healing rates with glues. Local sepsis should be eradicated with the use of preoperative setons, the track should be thoroughly curetted and the track irrigated with either saline or hydrogen peroxide. Preoperative bowel preparation has not consistently shown a benefit. Suturing the internal or external openings shut has been advocated, but not shown to confer a significant benefit ¹¹⁷.

It has been suggested that high failure rates with the glue may be a consequence of the glue not being retained in the fistula track ¹³⁰. To overcome this, some authors have recommended the use of stool softeners and avoiding straining and exercise in the postoperative period, although there are no data to support this. Other explanations for failure of fibrin glue include early resorption/degradation within 5–10 days of application, providing insufficient time for established healing ¹³¹, ¹³². A Phase 1 trial using Permacol® glue, which incorporates fibres suspended in fibrin glue to provide a physical scaffold for host cell proliferation after glue absorption, has shown promising results, but more, randomized, data are required ¹³². Newer autologous fibrin sealants have not shown any increased efficacy compared with conventional glues, with healing rates of up to 40% ¹³³. Research continues into the use of stem cell autologous suspensions for fistula application and the ADMIRE CD study used fibrin glue as the scaffold for allogeneic mesenchymal stem cell treatment of Crohn’s anal fistulas ¹³⁴. This may represent the main role for fibrin glue in the future.

Bioprosthetic plug

Another option is the insertion of a bioprosthetic plug. This is a cone-shaped plug made from animal tissue that’s used to block the internal opening of the fistula and preventing fecal material from entering. Anal fistula plugs procedure works well for blocking an anal fistula and there are no serious concerns about its safety. Anal fistula plugs provide a physical scaffold for in-growth of host regenerative and immune cells to promote healing and repair. The plugs degrade over a period of several weeks, by which time the repair process is established.

Accepting that rates of healing are variable, an anal fistula plug is an option for treating transsphincteric fistulas, especially where surgical options are considered to have a significant risk of jeopardizing continence. The additional cost of the plug should be taken into account when considering this surgical treatment. The initial reported high success rates of anal fistula plugs have not been maintained in later series, but, similar to fibrin glue, anal fistula plugs do not threaten continence. It remains uncertain as to which fistulas are best suited to fistula plug treatment.

Types of bioprosthetic plug

Several fistula plugs have been developed commercially, but the BioDesign Surgisis® Anal Fistula Plug (Cook Medical, Bloomington, Indiana, USA), composed of acellular, lyophilized porcine intestinal submucosa, is the most established ²⁰. Other plugs include the GORE Bio A® Fistula Plug (Flagstaff, Arizona, USA), a composite of polyglycolic acid and trimethylenecarbonate synthetic polymers 174, which has now been withdrawn by the manufacturer, the Pressfit® plug (Deco Med s.r.l., Venice, Italy), which is made from acellular dermal matrix, and the Curaseal AF® device (CuraSeal, Inc., Santa Clara, California, USA), which incorporates a silicone disc to reinforce occlusion of the internal fistula opening. Secure anchoring of the plug at the internal opening is a critical feature in the design of all these plugs.

Reported success rates for fistula healing with anal fistula plugs vary, ranging from 24% to 88% 175, reflecting differences in patient selection, plugs used, surgical technique, definition of healing and length of follow-up. In 2007, a Consensus Conference was held to establish uniformity in the indications and techniques for insertion of the Cook Medical fistula plug ¹³⁵. It concluded that all types of ano-cutaneous fistula were suitable for plug treatment, with transsphincteric fistulas being the ideal indication. Emphasis was placed on the prior control of associated sepsis and the use of seton drainage for 6–12 weeks preoperatively. Debridement or curettage of the track was discouraged, although gentle brushing to de-epithelialize the track was subsequently recommended, with saline or hydrogen peroxide irrigation being optional. Secure suturing of the plug to the internal opening/internal sphincter was considered important to prevent early extrusion of the plug, which had been reported as a cause for failure in some studies ¹³⁶. There was no evidence to support the routine use of a rectal mucosal flap to cover the plug. Suturing of the plug has been facilitated by modification of the original plug design to incorporate an internal ‘button’.

Initial encouraging results from Johnson et al. ¹³⁷ reporting closure rates of up to 87% have not been reproduced in later studies, which have presented mixed results. A randomized trial comparing the fistula plug with endorectal advancement flap (ERAF) was closed prematurely due to a high incidence of recurrence in the plug arm ¹³⁸. In another randomized controlled trial, comparing an acellular dermal matrix (ADM) plug vs fistula plug with endorectal advancement flap (ERAF), a healing rate of 82% was reported in the ADM group, with lower rates of recurrence (ADM plug 4% vs ERAF 28%) ¹³⁹. A subsequent meta-analysis comparing the plug with endorectal advancement flap (ERAF) failed to show any difference in recurrence rates or complications ¹⁴⁰. However, a recent robust multicentre randomized controlled trial of 94 patients with a transsphincteric fistula demonstrated clinical healing at 12 months in only 38% (15 of 44 patients) treated by collagen plug, compared with 66% (27 of 41 patients) treated by endorectal advancement flap (ERAF) ⁸⁵.

A potential disadvantage with the plug is the cost of the device, but this may be offset by a shorter hospital stay. In a study comparing fistula plug against endorectal advancement flap (ERAF), healing rates were similar, but the costs associated with endorectal advancement flap (ERAF) were higher due to a longer duration of hospital stay ¹⁴¹.

In a recent UK multicentre study (the NIHR FIAT trial) 152 patients were randomized to receive the Cook Biodesign fistula plug and compared with 152 patients receiving surgeon’s preference [cutting seton, ERAF, fistulotomy or ligation of intersphincteric fistula track (LIFT)] ¹⁴². Similar clinical fistula healing rates were observed at 12 months’ follow-up (plug 54% vs surgeon’s preference 57%) ¹⁴². Early plug extrusion remained a problem, despite the adoption of best surgical technique, occurring in 15% of cases. Rates of incontinence were low in both groups and there was no statistical difference in quality of life as measured by the Faecal Incontinence Quality of Life (FIQoL) and EQ-5D scoring systems. Complications rates were similar between the two groups, with the exception of increased early postoperative pain in the plug group, presumably associated with suturing to the internal anal sphincter.

The fistula plug has been successfully used in combination with other procedures, including the LIFT procedure. In a large, multicentre RCT, the LIFT–plug procedure was found to result in statistically significant higher healing rates compared with LIFT alone (LIFT–plug 94.0% vs LIFT 83.9%) ⁹⁷.

Most studies have included variable follow-up after surgery, ranging from 3 to 12 months. A long-term follow-up study, using MRI to assess fistula healing at 12 months after plug insertion, showed radiological evidence of a persistent fistula in up to 21% of patients, suggesting that reports of fistula healing at 12 months are likely to be an overestimate ¹⁴³.

Benefits in favor of the fistula plug include ease of use and lack of complications. No differences in complication rates have been reported between ERAF and AFP ¹⁴⁰, with documented complications including sepsis/abscess, recurrence and constipation ⁹⁷. Unlike some other techniques, no study has reported a detrimental effect to continence following use of a plug. Thus, the fistula plug is an option for treating a transsphincteric fistula. Uncertainty in healing efficacy is counterweighed by the lack of detrimental effect on continence. The cost of the device might be offset by shorter lengths of hospital stay.

Endoscopic ablation

In this procedure, an endoscope (a tube with a camera on the end) is put in the fistula. An electrode is then passed through the endoscope and used to seal the fistula.

Endoscopic ablation works well and there are no serious concerns about its safety.

Laser surgery

Radially emitting laser fiber treatment involves using a small laser beam to seal the fistula. There are uncertainties around how well it works, but there are no major safety concerns.

Laser therapy was described as a treatment option for anal fistula in the 1980s ¹⁴⁴ and more recently with a radial emitting laser probe ¹⁴⁵, the principle being to destroy epithelial cells lining the fistula track. It has been trialled in combination with fibrin glue ¹⁴⁶, although more recent work, using the laser in isolation, demonstrated healing in 9 of 11 patients at a median of 7.4 months ¹⁴⁵. In this study, the internal opening was closed using a flap in combination with laser ablation. A further larger study, recruiting 45 patients, found healing in 32 (71%) at a median of 30 months 215. All patients underwent placement of a loose seton prior to surgery, and 35 patients had a history of previous fistula surgery. A retrospective review of 50 patients treated by laser ablation showed ‘success’ in 41 (82%) at 12 months’ follow-up 216, which was mostly by phone, consequently these results need interpreting with caution. Wilhelm et al. 217 reported a series of 117 patients treated with the radial fibre fistula laser closing (FiLaC™) device. Patients in this series were followed for a median of 25 months (minimum 6 months) with primary healing in 64% of patients. A repeat procedure was performed in 31 patients who failed initial treatment, with overall healing achieved in 88% of patients. The treatment was associated with minimal alteration in anal control.

At present, laser ablation of a fistula track is in its infancy, with evidence supporting its use confined to a few case series. The best technique has not been established: for instance, is surgical closure of the internal opening necessary prior to laser ablation? Further larger studies, especially randomized trails against other sphincter-preserving techniques, are required to establish its role in treatment of anal fistulas.

Stem cell therapy

Autologous adipose-derived stem cells may represent a novel treatment option for complex fistulas, although as yet there is insufficient evidence to attest to its efficacy. As a technique it may be used in isolation or in combination with fibrin glue or advancement flaps. It has been used in patients with Crohn’s disease. Allogeneic, expanded, adipose-derived stem cells have been used in a randomized, multicentre, double-blind placebo-controlled study involving 212 patients ¹³⁴. The primary end-point was remission at 24 weeks. In the intention-to-treat analysis 53/107 (50%) receiving stem cells achieved this, compared with 36/105 (34%) in the placebo arm ¹³⁴. A separate multicentre, single-blind trial randomized 200 patients to stem cells alone, stem cells in combination with fibrin glue or fibrin glue alone, following closure of the internal opening ¹⁴⁷. There was no significant difference in healing rates between any of the groups, which were 40–50% at 12 months’ follow-up: no serious adverse events were reported. A further small case series of seven patients reported healing rates of five out of seven at 6 months and four out of seven at a median of 46 months Borowski DW, Gill TS, Agarwal AK, Tabaqchali MA, Garg DK, Bhaskar P. Adipose Tissue-Derived Regenerative Cell-Enhanced Lipofilling for Treatment of Cryptoglandular Fistulae-in-Ano: The ALFA Technique. Surg Innov. 2015 Dec;22(6):593-600. doi: 10.1177/1553350615572656. Long-term results of a Phase 2 trial in patients with Crohn’s disease reported healing rates of 75% at 24 months’ follow-up ¹⁴⁸. Recently reported work looked at whether autologous mesenchymal stem cells could heal fistulas in Crohn’s disease if applied in a bioabsorbable matrix ¹⁴⁹. At 6 months 10/12 patients had complete clinical healing. It is too soon to comment on the role of this complex treatment in the routine management of anal fistulas.

Fistula clips

The principle of fistula clips technique is to debride the primary track and close the internal opening with a tightly applied metal clip. The most extensively investigated apparatus is the OTSC® Proctology (Ovesco Endoscopy AG, Tu72074 Tübingen, Germany), which employs a nitinol clip. A recent case-series has demonstrated healing in 18 of 20 (90%) fistulas at 6 months ¹⁵⁰. This group consisted of 14 patients with a transsphincteric fistula and 6 with suprasphincteric fistulas, although details of the complexity of the tracks was not given. Two patients required removal of the clip as a result of delayed wound healing and discomfort. Another case-series of consecutive patients from a single institution used the OTSC® in refractory cases of anal fistula following previous surgery ¹⁵¹. Six of the 10 patients recruited had Crohn’s disease. Seven patients’ fistulas were healed at a median follow-up of approximately 8 months. The FISCLOSE trial is aimed at evaluating the efficacy and safety of a clip vs rectal mucosal advancement flap ¹⁵². The aim is to recruit 46 patients to two centers. The primary outcome is healing at 3 months. Secondary outcomes include healing at 6 and 12 months, anal pain, fecal incontinence and quality of life.

In a similar way to laser ablation, clipping the internal opening of a fistula is at an early stage of evolution, with a few encouraging case series having been published. Migration and pain, requiring removal of the clip at the request of patient, are significant risks that have been reported in the few studies which have been reported. Further larger studies, especially randomized trails against other sphincter-preserving techniques, are required to establish whether it has role in treatment of anal fistulas.

Video-assisted anal fistula treatment (VAAFT)

Video-assisted anal fistula treatment (VAAFT) consists of a diagnostic and a therapeutic phase. In the former, a fistuloscope and obturator are used to identify the internal opening as well as any secondary tracks and/or abscesses. The scope is inserted through the external opening and a glycine-mannitol solution infused to enable opening of the primary track and advancement under direct vision. The therapeutic phase involves destruction and cleaning of the track using cautery and further irrigation. One of the principles is closure of the internal opening using a circular/linear stapler, OTSC® nitinol clip or advancement/mucosal flap. Cyanoacrylate may be used to reinforce the closure of the internal opening, though the track must be left open to allow secretions to drain.

Work from Italy reported on 136 patients undergoing video-assisted anal fistula treatment (VAAFT) over a 5-year period ¹⁵³. Ninety-eight patients were followed up for a minimum of 6 months. Primary healing occurred in 72 (73%) patients within 2–3 months of surgery, with no major complications seen. Sixty-two patients were followed up for over a year, with healing noted in 52 (84%). A further study from Singapore reported on 41 patients treated with VAAFT ¹⁵⁴: all were cryptoglandular in etiology, though low intersphincteric fistulas and patients with abscesses were excluded. A number of approaches were used to obliterate the internal opening – stapling, advancement flap and OTSC® nitinol clip. Eleven patients had undergone previous fistula surgery. Overall primary healing was seen in 29 (71%) patients at a median follow-up of 34 months, with the best results seen with VAAFT in combination with the OTSC® nitinol clip. This approach has also been used in patients with Crohn’s disease in combination with an advancement flap ¹⁵⁵. Success in the 13 patients recruited was defined as closure of both internal and external openings, absence of drainage without requirement for intervention and no abscess formation. All patients had complex fistulae, five were on biological agents and four had a proximal stoma. At a mean follow-up of 9 months 9 of 11 patients, where video-assisted anal fistula treatment (VAAFT) was technically possible, were deemed a success, and no deterioration in continence was observed. VAAFT has also been reported in a paediatric population ¹⁵⁶. Thirteen procedures were performed on nine children (mean age 9.6 years). One was associated with Crohn’s disease, though only five were described as idiopathic. All patients who underwent a complete VAAFT (n = 8) were healed at 10 months.

Vvideo-assisted anal fistula treatment (VAAFT) is another novel treatment that shows some promise, although it is far from clear which part of the treatment is important and whether the video element is vital to its success or whether thorough cleaning of the track and secure closure of the internal opening is equally successful, saving the investment in the video technology. Proponents argue that the diagnostic phase finds tracks that MRI has missed, although evidence to support this assertion is lacking. More detailed studies are required before this dilemma can be resolved and the role of VAAFT be defined.

Anal fistula in Crohn disease

Anal fistula in Crohn disease patients is a severe disease to treat, but early recognition and diagnosis are critical to effective therapy. These patients should be referred to a gastroenterologist and receive anti-TNF alpha therapy as their primary treatment for fistula disease. After medical treatment, if the fistula persists, setons are the most commonly used primary surgical option in these patients with reasonable healing rates after anti-TNF alpha therapy ¹⁵⁷. Crohn disease patients often are misdiagnosed and have delays in care and also may experience prolonged waiting periods to obtain their medications; thus, a comprehensive care team may be more effective in the management of these patients ¹⁵⁷. Infliximab is the primary treatment for these patients. In patients receiving infliximab therapy, higher blood levels of the drug have been associated with improved healing rates ¹⁵⁸. Patients with Chron disease are likely to have concomitant proctitis, which is revealed by preoperative imaging. A study of 126 patients with anal fistulas who underwent preoperative MRI found that MRI findings of concomitant rectal inflammation were more closely associated with Crohn disease ¹⁵⁹.

The International Organisation for Inflammatory Bowel Diseases (IOIBD) global consensus guidelines emphasize the importance of evaluation of the rectum in these patients as their disease may often affect the rectal mucosa and anorectal area simultaneously. In a study of 36 pediatric and adult patients with fistulizing Crohn disease, a cutoff of 2.5 cm seen on MRI predicted patients who responded to infliximab therapy and those with the persistence of illness ¹⁶⁰. A few studies have shown effective healing rates around 67-90% of combined seton and anti-TNF alpha therapy in Crohn disease patients that were retrospective in nature ¹⁶¹. A large meta-analysis comparing healing of primary seton versus infliximab failed to determine which was superior as the studies varied in outcomes ¹⁶².

Anal fistula prognosis

Prognosis of the anorectal fistula is variable depending on the cause. In anal fistulas of cryptoglandular origin healing rates for simple fistulas approach 80%, and that of complex fistulas are around 60% for sphincter preserving operation ¹⁶³. Recurrence of anal fistula is higher in obese patients, smokers, and those with a history of anal surgery. Anatomical factors including multiple fistula tracts, high transphincteric fistula, inability to determine an internal opening, seton placement, and horseshoe abscesses were also associated with a higher rate of recurrence ¹⁷. Recurrence of the fistula often occurs within the first year of treatment ¹⁶⁴.

Setons have been used with much success up to 80 to 90% healing rates, but these are healing rates measured after six months. In general, a fistula that is treated with a fistulotomy or fistulectomy, depending on the wound size, should be entirely healed by 12 weeks. If drainage is increased or persistent up the twelfth week that the fistula recurred or did not close completely. Causes for failure of surgical therapy include incomplete division of the fistula in a fistulotomy or incomplete resection or obliteration of tract in a fistulectomy. In the LIFT procedure, leaving a long fistula tract behind and incomplete ligation of the fistula tract are possible causes of failure. In anal-cutaneous or rectal mucosal advancement flap techniques, if the flap fails, the fistula will either not heal or will recur. Smoking is a risk factor for failure of treatment with flap, as well as Crohn disease ⁸⁰. This is often secondary to the inadequate blood supply of the flap, as evidenced by improved healing rates when the muscular layer is used in the flap.

Failure of anal fistula plugs to allow fistulas to heal can be attributed to multiple reasons including, not completely covering the plug internally, incomplete debridement of the fistula tract, and premature dislodgement of the fistula plug. Setons that are removed too early may lead to the fistula not healing if the tract has not migrated sufficiently to allow the fistula to heal. Some setons may lead to a lower fistula that then requires a fistulotomy for complete healing to occur.

Depending on the initial procedure performed, additional procedures are used to treat recurrence fistula. When a fistula recurs, an MRI is helpful to determine its course, and an exam under anesthesia should be performed to characterize the fistula tract. Treatment is based on the type of fistula present, which may be different on recurrence than on complex fistula. Because the risk of incontinence is increased with repeated anorectal surgeries, a sphincter preserving approach is best utilized in the treatment of recurrent fistula, mainly if a fistulotomy or fistulectomy was the primary treatment. LIFT procedure is an option for recurrent fistulas. A failed LIFT procedure may be followed by a repeat LIFT procedure or an advancement flap procedure or seton. One study which evaluated outcomes of 53 patients who failed LIFT procedure and went on to undergo an endorectal advancement flap or fistulotomy staged with seton showed a 50% healing rate ¹⁶⁵. Of patients with a high transphincteric fistula, those with a horseshoe extension of the fistula may have improved success with anal advancement flap repair ⁸¹.

Setons used as the primary treatment should be considered a staged procedure and followed by a fistulotomy. Anal fistula plug procedure that has failed may be followed by a seton, advancement flap, LIFT, or even fistulotomy depending on the location of the fistula. A failed flap may be repeated using tissue from a different site. VAAFT is a safe treatment option when repeated for failed initial VAAFT with increased healing rates on the repeat procedure ¹⁶⁶.

1. Hokkanen SR, Boxall N, Khalid JM, Bennett D, Patel H. Prevalence of anal fistula in the United Kingdom. World J Clin Cases. 2019 Jul 26;7(14):1795-1804. doi: 10.12998/wjcc.v7.i14.1795[↩][↩]
2. Vuković, Milivoje. (2021). SETON IN THE TREATMENT OF ANAL FISTULAS – USE OF DIFFERENT MATERIALS. https://www.researchgate.net/publication/349109802_SETON_IN_THE_TREATMENT_OF_ANAL_FISTULAS_-_USE_OF_DIFFERENT_MATERIALS[↩]
3. Gosselink MP, van Onkelen RS, Schouten WR. The cryptoglandular theory revisited. Colorectal Dis. 2015 Dec;17(12):1041-3. doi: 10.1111/codi.13161[↩]
4. Anal fistula. https://www.mayoclinic.org/diseases-conditions/anal-fistula/symptoms-causes/syc-20352871[↩]
5. Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol. 1984;73(4):219-24.[↩][↩][↩]
6. Abcarian H. Anorectal infection: abscess-fistula. Clin Colon Rectal Surg. 2011 Mar;24(1):14-21. doi: 10.1055/s-0031-1272819[↩]
7. Zanotti C, Martinez-Puente C, Pascual I, Pascual M, Herreros D, García-Olmo D. An assessment of the incidence of fistula-in-ano in four countries of the European Union. Int J Colorectal Dis. 2007 Dec;22(12):1459-62. doi: 10.1007/s00384-007-0334-7[↩]
8. García-Olmo D, Van Assche G, Tagarro I, Carmen Diez M, Richard MP, Khalid JM. The prevalence of perianal fistulas in Europe: estimate from literature review and from a United Kingdom population-based database analysis. In ESCP, Nice, France, 2018[↩]
9. Felt-Bersma RJ, Bartelsman JF. Haemorrhoids, rectal prolapse, anal fissure, peri-anal fistulae and sexually transmitted diseases. Best Pract Res Clin Gastroenterol. 2009;23(4):575-92. doi: 10.1016/j.bpg.2009.04.010[↩]
10. Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr;122(4):875-80. doi: 10.1053/gast.2002.32362[↩]
11. Milito G, Lisi G, Aronadio E, Campanelli M, Venditti D, Grande S, Grande M. LigasureTM hemorrhoidectomy: how we do. Minerva Gastroenterol Dietol. 2017 Mar;63(1):44-49. doi: 10.23736/S1121-421X.16.02343-6[↩]
12. Bjelanovic Z, Draskovic M, Veljovic M, Lekovic I, Karanikolas M, Stamenkovic D. Transanal hemorrhoid dearterialization is a safe and effective outpatient procedure for the treatment of hemorrhoidal disease. Cir Esp. 2016 Dec;94(10):588-594. English, Spanish. doi: 10.1016/j.ciresp.2016.07.002[↩]
13. Scieux C, Barnes R, Bianchi A, Casin I, Morel P, Perol Y. Lymphogranuloma venereum: 27 cases in Paris. J Infect Dis. 1989 Oct;160(4):662-8. doi: 10.1093/infdis/160.4.662[↩]
14. Gupta PJ. Ano-perianal tuberculosis–solving a clinical dilemma. Afr Health Sci. 2005 Dec;5(4):345-7. doi: 10.5555/afhs.2005.5.4.345[↩]
15. Lenton S, Crouchman M. Keeping babies in prison. BMJ. 1992 Jun 6;304(6840):1511. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1882214/pdf/bmj00076-0065a.pdf[↩]
16. Ji L, Zhang Y, Xu L, Wei J, Weng L, Jiang J. Advances in the Treatment of Anal Fistula: A Mini-Review of Recent Five-Year Clinical Studies. Front Surg. 2021 Feb 11;7:586891. doi: 10.3389/fsurg.2020.586891[↩][↩]
17. Mei Z, Wang Q, Zhang Y, Liu P, Ge M, Du P, Yang W, He Y. Risk Factors for Recurrence after anal fistula surgery: A meta-analysis. Int J Surg. 2019 Sep;69:153-164. doi: 10.1016/j.ijsu.2019.08.003[↩][↩]
18. Emile SH, Elfeki H, Thabet W, Sakr A, Magdy A, El-Hamed TMA, Omar W, Khafagy W. Predictive factors for recurrence of high transsphincteric anal fistula after placement of seton. J Surg Res. 2017 Jun 1;213:261-268. doi: 10.1016/j.jss.2017.02.053[↩]
19. Alasari S, Kim NK. Overview of anal fistula and systematic review of ligation of the intersphincteric fistula tract (LIFT). Tech Coloproctol. 2014 Jan;18(1):13-22. doi: 10.1007/s10151-013-1050-7[↩]
20. Williams, G., Williams, A., Tozer, P., Phillips, R., Ahmad, A., Jayne, D. and Maxwell-Armstrong, C. (2018), The treatment of anal fistula: second ACPGBI Position Statement – 2018. Colorectal Dis, 20: 5-31. https://doi.org/10.1111/codi.14054[↩][↩][↩][↩][↩][↩][↩][↩][↩][↩][↩][↩]
21. Rosen L. Anorectal abscess-fistulae. Surg Clin North Am. 1994 Dec. 74(6):1293-308.[↩]
22. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976;63(1):1-12[↩]
23. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976 Jan. 63(1):1-12.[↩][↩]
24. Gold, S.L., Cohen-Mekelburg, S., Schneider, Y., & Steinlauf, A.F. (2018). Perianal Fistulas in Patients With Crohn’s Disease, Part 1: Current Medical Management. Gastroenterology & hepatology, 14 8, 470-481[↩]
25. Mocanu V, Dang JT, Ladak F, Tian C, Wang H, Birch DW, Karmali S. Antibiotic use in prevention of anal fistulas following incision and drainage of anorectal abscesses: A systematic review and meta-analysis. Am J Surg. 2019 May;217(5):910-917. doi: 10.1016/j.amjsurg.2019.01.015[↩]
26. Manookian CM, Sokol TP, Headrick C, Fleshner PR. Does HIV status influence the anatomy of anal fistulas? Dis Colon Rectum. 1998 Dec;41(12):1529-33. doi: 10.1007/BF02237301[↩]
27. Gonzalez-Ruiz C, Heartfield W, Briggs B, Vukasin P, Beart RW. Anorectal pathology in HIV/AIDS-infected patients has not been impacted by highly active antiretroviral therapy. Dis Colon Rectum. 2004 Sep;47(9):1483-6. doi: 10.1007/s10350-004-0606-z[↩]
28. Assi R, Hashim PW, Reddy VB, Einarsdottir H, Longo WE. Sexually transmitted infections of the anus and rectum. World J Gastroenterol. 2014 Nov 7;20(41):15262-8. doi: 10.3748/wjg.v20.i41.15262[↩]
29. Do NL, Nagle D, Poylin VY. Radiation proctitis: current strategies in management. Gastroenterol Res Pract. 2011;2011:917941. doi: 10.1155/2011/917941[↩]
30. Signorello LB, Harlow BL, Chekos AK, Repke JT. Midline episiotomy and anal incontinence: retrospective cohort study. BMJ. 2000 Jan 8;320(7227):86-90. doi: 10.1136/bmj.320.7227.86[↩]
31. Eisenhammer S. A new approach to the anorectal fistulous abscess based on the high intermuscular lesion. Surg Gynecol Obstet. 1958 May;106(5):595-9.[↩]
32. Parks AG. Pathogenesis and treatment of fistuila-in-ano. Br Med J. 1961 Feb 18;1(5224):463-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1953161/pdf/brmedj02881-0047.pdf[↩]
33. Mitalas LE, van Onkelen RS, Monkhorst K, Zimmerman DD, Gosselink MP, Schouten WR. Identification of epithelialization in high transsphincteric fistulas. Tech Coloproctol. 2012 Apr;16(2):113-7. doi: 10.1007/s10151-011-0803-4[↩][↩]
34. Naldini G, Cerullo G, Mascagni D, Orlandi S, Menconi C, Zeri K, Felli E, Martellucci J. Hiding intersphincteric and transphincteric sepsis in a novel pathological approach to chronic anal fissure. Surg Innov. 2012 Mar;19(1):33-6. doi: 10.1177/1553350611410990[↩][↩]
35. Devaraj B, Khabassi S, Cosman BC. Recent smoking is a risk factor for anal abscess and fistula. Dis Colon Rectum. 2011 Jun;54(6):681-5. doi: 10.1007/DCR.0b013e31820e7c7a[↩]
36. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021 Jun;160(7):2512-2556.e9. doi: 10.1053/j.gastro.2021.04.023[↩]
37. Hamadani A, Haigh PI, Liu IL, Abbas MA. Who is at risk for developing chronic anal fistula or recurrent anal sepsis after initial perianal abscess? Dis Colon Rectum. 2009 Feb;52(2):217-21. doi: 10.1007/DCR.0b013e31819a5c52[↩][↩]
38. Lohsiriwat V, Yodying H, Lohsiriwat D. Incidence and factors influencing the development of fistula-in-ano after incision and drainage of perianal abscesses. J Med Assoc Thai. 2010 Jan;93(1):61-5.[↩][↩]
39. Sahnan K, Askari A, Adegbola SO, Tozer PJ, Phillips RKS, Hart A, Faiz OD. Natural history of anorectal sepsis. Br J Surg. 2017 Dec;104(13):1857-1865. doi: 10.1002/bjs.10614[↩]
40. Lunniss PJ, Faris B, Rees HC, Heard S, Phillips RK. Histological and microbiological assessment of the role of microorganisms in chronic anal fistula. Br J Surg. 1993 Aug;80(8):1072. doi: 10.1002/bjs.1800800853[↩]
41. Seow-Choen F, Hay AJ, Heard S, Phillips RK. Bacteriology of anal fistulae. Br J Surg. 1992 Jan;79(1):27-8. doi: 10.1002/bjs.1800790107[↩]
42. Tozer PJ, Rayment N, Hart AL, Daulatzai N, Murugananthan AU, Whelan K, Phillips RK. What role do bacteria play in persisting fistula formation in idiopathic and Crohn’s anal fistula? Colorectal Dis. 2015 Mar;17(3):235-41. doi: 10.1111/codi.12810[↩]
43. van Onkelen RS, Mitalas LE, Gosselink MP, van Belkum A, Laman JD, Schouten WR. Assessment of microbiota and peptidoglycan in perianal fistulas. Diagn Microbiol Infect Dis. 2013 Jan;75(1):50-4. doi: 10.1016/j.diagmicrobio.2012.09.012[↩]
44. El-Tawil AM. Mechanism of non-specific-fistula-in-ano: Hormonal aspects-Review. Pathophysiology. 2012 Feb;19(1):55-9. doi: 10.1016/j.pathophys.2011.07.004[↩]
45. van Koperen PJ, ten Kate FJ, Bemelman WA, Slors JF. Histological identification of epithelium in perianal fistulae: a prospective study. Colorectal Dis. 2010 Sep;12(9):891-5. doi: 10.1111/j.1463-1318.2009.01880.x[↩]
46. Ortega AE. Requiem on the Deep Postanal Space and Supralevator Abscesses. Dis Colon Rectum. 2016 Jul;59(7):e409. doi: 10.1097/DCR.0000000000000625[↩]
47. Yassin NA, Dardanov D, Phillips RK. Sepsis, CT, and the Deep Postanal Space: A Riddle, Wrapped in a Mystery, Inside an Enigma. Dis Colon Rectum. 2015 Nov;58(11):1111-3. doi: 10.1097/DCR.0000000000000469[↩]
48. Williams JG. Complex Fistula-In-Ano: A Small Step Forward in Understanding? Dis Colon Rectum. 2016 Aug;59(8):707-9. doi: 10.1097/DCR.0000000000000629[↩]
49. Zhang H, Zhou ZY, Hu B, Liu DC, Peng H, Xie SK, Su D, Ren DL. Clinical Significance of 2 Deep Posterior Perianal Spaces to Complex Cryptoglandular Fistulas. Dis Colon Rectum. 2016 Aug;59(8):766-74. doi: 10.1097/DCR.0000000000000628[↩]
50. Visscher AP, Schuur D, Roos R, Van der Mijnsbrugge GJ, Meijerink WJ, Felt-Bersma RJ. Long-term follow-up after surgery for simple and complex cryptoglandular fistulas: fecal incontinence and impact on quality of life. Dis Colon Rectum. 2015 May;58(5):533-9. doi: 10.1097/DCR.0000000000000352[↩]
51. Seneviratne SA, Samarasekera DN, Kotalawala W. Quality of life following surgery for recurrent fistula-in-ano. Tech Coloproctol. 2009 Sep;13(3):215-7. doi: 10.1007/s10151-009-0517-z[↩]
52. Abbas MA, Jackson CH, Haigh PI. Predictors of outcome for anal fistula surgery. Arch Surg. 2011 Sep;146(9):1011-6. doi: 10.1001/archsurg.2011.197[↩]
53. Jordán J, Roig JV, García-Armengol J, García-Granero E, Solana A, Lledó S. Risk factors for recurrence and incontinence after anal fistula surgery. Colorectal Dis. 2010 Mar;12(3):254-60. doi: 10.1111/j.1463-1318.2009.01806.x[↩]
54. Toyonaga T, Matsushima M, Kiriu T, Sogawa N, Kanyama H, Matsumura N, Shimojima Y, Hatakeyama T, Tanaka Y, Suzuki K, Tanaka M. Factors affecting continence after fistulotomy for intersphincteric fistula-in-ano. Int J Colorectal Dis. 2007 Sep;22(9):1071-5. doi: 10.1007/s00384-007-0277-z[↩]
55. Bharucha AE, Rao SSC, Shin AS. Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1844-1854. doi: 10.1016/j.cgh.2017.08.023[↩]
56. Atkin GK, Martins J, Tozer P, Ranchod P, Phillips RK. For many high anal fistulas, lay open is still a good option. Tech Coloproctol. 2011 Jun;15(2):143-50. doi: 10.1007/s10151-011-0676-6[↩]
57. Tozer P, Sala S, Cianci V, Kalmar K, Atkin GK, Rahbour G, Ranchod P, Hart A, Phillips RK. Fistulotomy in the tertiary setting can achieve high rates of fistula cure with an acceptable risk of deterioration in continence. J Gastrointest Surg. 2013 Nov;17(11):1960-5. doi: 10.1007/s11605-013-2198-1[↩]
58. Chalya PL, Mabula JB. Fistulectomy versus fistulotomy with marsupialisation in the treatment of low fistula-in- ano: a prospective randomized controlled trial. Tanzan J Health Res. 2013 Jul;15(3):193-8. doi: 10.4314/thrb.v15i3.7[↩][↩]
59. Ho YH, Tan M, Leong AF, Seow-Choen F. Marsupialization of fistulotomy wounds improves healing: a randomized controlled trial. Br J Surg. 1998 Jan;85(1):105-7. doi: 10.1046/j.1365-2168.1998.00529.x[↩][↩]
60. Jain BK, Vaibhaw K, Garg PK, Gupta S, Mohanty D. Comparison of a fistulectomy and a fistulotomy with marsupialization in the management of a simple anal fistula: a randomized, controlled pilot trial. J Korean Soc Coloproctol. 2012 Apr;28(2):78-82. doi: 10.3393/jksc.2012.28.2.78[↩][↩]
61. Pescatori M, Ayabaca SM, Cafaro D, Iannello A, Magrini S. Marsupialization of fistulotomy and fistulectomy wounds improves healing and decreases bleeding: a randomized controlled trial. Colorectal Dis. 2006 Jan;8(1):11-4. doi: 10.1111/j.1463-1318.2005.00835.x[↩][↩]
62. Galis-Rozen E, Tulchinsky H, Rosen A, Eldar S, Rabau M, Stepanski A, Klausner JM, Ziv Y. Long-term outcome of loose seton for complex anal fistula: a two-centre study of patients with and without Crohn’s disease. Colorectal Dis. 2010 Apr;12(4):358-62. doi: 10.1111/j.1463-1318.2009.01796.x[↩]
63. Lim CH, Shin HK, Kang WH, Park CH, Hong SM, Jeong SK, Kim JY, Yang HK. The use of a staged drainage seton for the treatment of anal fistulae or fistulous abscesses. J Korean Soc Coloproctol. 2012 Dec;28(6):309-14. doi: 10.3393/jksc.2012.28.6.309[↩]
64. M GP, M GC, S GU, L SN, P ME, R FB, D AZ. Modified loose-seton technique for the treatment of complex anal fistulas. Colorectal Dis. 2010 Oct;12(10 Online):e310-3. doi: 10.1111/j.1463-1318.2010.02195.x[↩]
65. Subhas G, Gupta A, Balaraman S, Mittal VK, Pearlman R. Non-cutting setons for progressive migration of complex fistula tracts: a new spin on an old technique. Int J Colorectal Dis. 2011 Jun;26(6):793-8. doi: 10.1007/s00384-011-1189-5[↩]
66. Kelly ME, Heneghan HM, McDermott FD, Nason GJ, Freeman C, Martin ST, Winter DC. The role of loose seton in the management of anal fistula: a multicenter study of 200 patients. Tech Coloproctol. 2014 Oct;18(10):915-9. doi: 10.1007/s10151-014-1186-0[↩]
67. Ege B, Leventoğlu S, Menteş BB, Yılmaz U, Öner AY. Hybrid seton for the treatment of high anal fistulas: results of 128 consecutive patients. Tech Coloproctol. 2014 Feb;18(2):187-93. doi: 10.1007/s10151-013-1021-z[↩][↩][↩]
68. Rosen DR, Kaiser AM. Definitive seton management for transsphincteric fistula-in-ano: harm or charm? Colorectal Dis. 2016 May;18(5):488-95. doi: 10.1111/codi.13120[↩][↩]
69. Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting seton treatment for anal fistula. Colorectal Dis. 2009 Jul;11(6):564-71. doi: 10.1111/j.1463-1318.2008.01713.x[↩][↩]
70. Raslan SM, Aladwani M, Alsanea N. Evaluation of the cutting seton as a method of treatment for perianal fistula. Ann Saudi Med. 2016 May-Jun;36(3):210-5. doi: 10.5144/0256-4947.2016.210[↩][↩]
71. Leventoğlu S, Ege B, Menteş BB, Yörübulut M, Soydan S, Aytaç B. Treatment for horseshoe fistula with the modified Hanley procedure using a hybrid seton: results of 21 cases. Tech Coloproctol. 2013 Aug;17(4):411-7. doi: 10.1007/s10151-012-0952-0[↩][↩]
72. Hammond TM, Knowles CH, Porrett T, Lunniss PJ. The Snug Seton: short and medium term results of slow fistulotomy for idiopathic anal fistulae. Colorectal Dis. 2006 May;8(4):328-37. doi: 10.1111/j.1463-1318.2005.00926.x[↩][↩][↩]
73. Memon AA, Murtaza G, Azami R, Zafar H, Chawla T, Laghari AA. Treatment of complex fistula in ano with cable-tie seton: a prospective case series. ISRN Surg. 2011;2011:636952. doi: 10.5402/2011/636952[↩][↩]
74. Izadpanah A, Rezazadehkermani M, Hosseiniasl SM, Farghadin A, Ghahramani L, Bananzadeh A, Roshanravan R, Izadpanah A. Pulling Seton: Combination of mechanisms. Adv Biomed Res. 2016 Apr 19;5:68. doi: 10.4103/2277-9175.180637[↩][↩]
75. Vial M, Parés D, Pera M, Grande L. Faecal incontinence after seton treatment for anal fistulae with and without surgical division of internal anal sphincter: a systematic review. Colorectal Dis. 2010 Mar;12(3):172-8. doi: 10.1111/j.1463-1318.2009.01810.x[↩]
76. Kamrava A, Collins JC. A decade of selective use of adjustable cutting seton combined with fistulotomy for anal fistula. Am Surg. 2011 Oct;77(10):1377-80.[↩]
77. Tozer PJ, Balmforth D, Kayani B, Rahbour G, Hart AL, Phillips RK. Surgical management of rectovaginal fistula in a tertiary referral centre: many techniques are needed. Colorectal Dis. 2013 Jul;15(7):871-7. doi: 10.1111/codi.12114[↩]
78. Zimmerman DD, Delemarre JB, Gosselink MP, Hop WC, Briel JW, Schouten WR. Smoking affects the outcome of transanal mucosal advancement flap repair of trans-sphincteric fistulas. Br J Surg. 2003 Mar;90(3):351-4. doi: 10.1002/bjs.4044[↩]
79. Ellis CN, Clark S. Effect of tobacco smoking on advancement flap repair of complex anal fistulas. Dis Colon Rectum. 2007 Apr;50(4):459-63. doi: 10.1007/s10350-006-0829-2[↩]
80. Mizrahi N, Wexner SD, Zmora O, Da Silva G, Efron J, Weiss EG, Vernava AM 3rd, Nogueras JJ. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum. 2002 Dec;45(12):1616-21. doi: 10.1097/01.DCR.0000037654.01119.CD[↩][↩]
81. van Onkelen RS, Gosselink MP, Thijsse S, Schouten WR. Predictors of outcome after transanal advancement flap repair for high transsphincteric fistulas. Dis Colon Rectum. 2014 Aug;57(8):1007-11. doi: 10.1097/DCR.0000000000000154[↩][↩]
82. Boenicke L, Karsten E, Zirngibl H, Ambe P. Advancement Flap for Treatment of Complex Cryptoglandular Anal Fistula: Prediction of Therapy Success or Failure Using Anamnestic and Clinical Parameters. World J Surg. 2017 Sep;41(9):2395-2400. doi: 10.1007/s00268-017-4006-7[↩]
83. van Koperen PJ, Bemelman WA, Gerhards MF, Janssen LW, van Tets WF, van Dalsen AD, Slors JF. The anal fistula plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. Dis Colon Rectum. 2011 Apr;54(4):387-93. doi: 10.1007/DCR.0b013e318206043e[↩]
84. Mitalas LE, van Wijk JJ, Gosselink MP, Doornebosch P, Zimmerman DD, Schouten WR. Seton drainage prior to transanal advancement flap repair: useful or not? Int J Colorectal Dis. 2010 Dec;25(12):1499-502. doi: 10.1007/s00384-010-0993-7[↩]
85. Bondi J, Avdagic J, Karlbom U, Hallböök O, Kalman D, Šaltytė Benth J, Naimy N, Øresland T. Randomized clinical trial comparing collagen plug and advancement flap for trans-sphincteric anal fistula. Br J Surg. 2017 Aug;104(9):1160-1166. doi: 10.1002/bjs.10549[↩][↩][↩][↩]
86. Balciscueta Z, Uribe N, Balciscueta I, Andreu-Ballester JC, García-Granero E. Rectal advancement flap for the treatment of complex cryptoglandular anal fistulas: a systematic review and meta-analysis. Int J Colorectal Dis. 2017 May;32(5):599-609. doi: 10.1007/s00384-017-2779-7[↩][↩][↩]
87. Dubsky PC, Stift A, Friedl J, Teleky B, Herbst F. Endorectal advancement flaps in the treatment of high anal fistula of cryptoglandular origin: full-thickness vs. mucosal-rectum flaps. Dis Colon Rectum. 2008 Jun;51(6):852-7. doi: 10.1007/s10350-008-9242-3[↩]
88. Ozuner G, Hull TL, Cartmill J, Fazio VW. Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. Dis Colon Rectum. 1996 Jan;39(1):10-4. doi: 10.1007/BF02048261[↩]
89. Ortíz H, Marzo J. Endorectal flap advancement repair and fistulectomy for high trans-sphincteric and suprasphincteric fistulas. Br J Surg. 2000 Dec;87(12):1680-3. doi: 10.1046/j.1365-2168.2000.01582.x[↩]
90. Lewis P, Bartolo DC. Treatment of trans-sphincteric fistulae by full thickness anorectal advancement flaps. Br J Surg. 1990 Oct;77(10):1187-9. doi: 10.1002/bjs.1800771033[↩]
91. Stone JM, Goldberg SM. The endorectal advancement flap procedure. Int J Colorectal Dis. 1990 Dec;5(4):232-5. doi: 10.1007/BF00303283[↩]
92. Marchesa P, Hull TL, Fazio VW. Advancement sleeve flaps for treatment of severe perianal Crohn’s disease. Br J Surg. 1998 Dec;85(12):1695-8. doi: 10.1046/j.1365-2168.1998.00959.x[↩]
93. Amin SN, Tierney GM, Lund JN, Armitage NC. V-Y advancement flap for treatment of fistula-in-ano. Dis Colon Rectum. 2003 Apr;46(4):540-3. doi: 10.1007/s10350-004-6596-z[↩][↩]
94. Nelson RL, Cintron J, Abcarian H. Dermal island-flap anoplasty for transsphincteric fistula-in-ano: assessment of treatment failures. Dis Colon Rectum. 2000 May;43(5):681-4. doi: 10.1007/BF02235588[↩][↩]
95. Rojanasakul A, Pattanaarun J, Sahakitrungruang C, Tantiphlachiva K. Total anal sphincter saving technique for fistula-in-ano; the ligation of intersphincteric fistula tract. J Med Assoc Thai. 2007 Mar;90(3):581-6.[↩]
96. Mushaya C, Bartlett L, Schulze B, Ho YH. Ligation of intersphincteric fistula tract compared with advancement flap for complex anorectal fistulas requiring initial seton drainage. Am J Surg. 2012 Sep;204(3):283-9. doi: 10.1016/j.amjsurg.2011.10.025[↩][↩]
97. Han JG, Wang ZJ, Zheng Y, Chen CW, Wang XQ, Che XM, Song WL, Cui JJ. Ligation of Intersphincteric Fistula Tract vs Ligation of the Intersphincteric Fistula Tract Plus a Bioprosthetic Anal Fistula Plug Procedure in Patients With Transsphincteric Anal Fistula: Early Results of a Multicenter Prospective Randomized Trial. Ann Surg. 2016 Dec;264(6):917-922. doi: 10.1097/SLA.0000000000001562[↩][↩][↩][↩]
98. Madbouly KM, El Shazly W, Abbas KS, Hussein AM. Ligation of intersphincteric fistula tract versus mucosal advancement flap in patients with high transsphincteric fistula-in-ano: a prospective randomized trial. Dis Colon Rectum. 2014 Oct;57(10):1202-8. doi: 10.1097/DCR.0000000000000194[↩][↩]
99. Sileri P, Giarratano G, Franceschilli L, Limura E, Perrone F, Stazi A, Toscana C, Gaspari AL. Ligation of the intersphincteric fistula tract (LIFT): a minimally invasive procedure for complex anal fistula: two-year results of a prospective multicentric study. Surg Innov. 2014 Oct;21(5):476-80. doi: 10.1177/1553350613508018[↩]
100. Abcarian AM, Estrada JJ, Park J, Corning C, Chaudhry V, Cintron J, Prasad L, Abcarian H. Ligation of intersphincteric fistula tract: early results of a pilot study. Dis Colon Rectum. 2012 Jul;55(7):778-82. doi: 10.1097/DCR.0b013e318255ae8a[↩]
101. Ooi K, Skinner I, Croxford M, Faragher I, McLaughlin S. Managing fistula-in-ano with ligation of the intersphincteric fistula tract procedure: the Western Hospital experience. Colorectal Dis. 2012 May;14(5):599-603. doi: 10.1111/j.1463-1318.2011.02723.x[↩]
102. Liu WY, Aboulian A, Kaji AH, Kumar RR. Long-term results of ligation of intersphincteric fistula tract (LIFT) for fistula-in-ano. Dis Colon Rectum. 2013 Mar;56(3):343-7. doi: 10.1097/DCR.0b013e318278164c[↩]
103. Parthasarathi R, Gomes RM, Rajapandian S, Sathiamurthy R, Praveenraj P, Senthilnathan P, Palanivelu C. Ligation of the intersphincteric fistula tract for the treatment of fistula-in-ano: experience of a tertiary care centre in South India. Colorectal Dis. 2016 May;18(5):496-502. doi: 10.1111/codi.13162[↩]
104. Altomare DF, Greco VJ, Tricomi N, Arcanà F, Mancini S, Rinaldi M, Pulvirenti d’Urso A, La Torre F. Seton or glue for trans-sphincteric anal fistulae: a prospective randomized crossover clinical trial. Colorectal Dis. 2011 Jan;13(1):82-6. doi: 10.1111/j.1463-1318.2009.02056.x[↩][↩][↩]
105. Cho DY. Endosonographic criteria for an internal opening of fistula-in-ano. Dis Colon Rectum. 1999 Apr;42(4):515-8. doi: 10.1007/BF02234179[↩]
106. Schulze B, Ho YH. Management of complex anorectal fistulas with seton drainage plus partial fistulotomy and subsequent ligation of intersphincteric fistula tract (LIFT). Tech Coloproctol. 2015 Feb;19(2):89-95. doi: 10.1007/s10151-014-1245-6[↩]
107. Romaniszyn M, Walega PJ, Nowak W. Efficacy of lift (ligation of intersphincteric fistula tract) for complex and recurrent anal fistulas–a single-center experience and a review of the literature. Pol Przegl Chir. 2015 Feb 3;86(11):532-6. doi: 10.2478/pjs-2014-0094[↩]
108. van Onkelen RS, Gosselink MP, Schouten WR. Ligation of the intersphincteric fistula tract in low transsphincteric fistulae: a new technique to avoid fistulotomy. Colorectal Dis. 2013 May;15(5):587-91. doi: 10.1111/codi.12030[↩]
109. Chen HJ, Sun GD, Zhu P, Zhou ZL, Chen YG, Yang BL. Effective and long-term outcome following ligation of the intersphincteric fistula tract (LIFT) for transsphincteric fistula. Int J Colorectal Dis. 2017 Apr;32(4):583-585. doi: 10.1007/s00384-016-2723-2[↩]
110. Tan KK, Lee PJ. Early experience of reinforcing the ligation of the intersphincteric fistula tract procedure with a bioprosthetic graft (BioLIFT) for anal fistula. ANZ J Surg. 2014 Apr;84(4):280-3. doi: 10.1111/ans.12242[↩]
111. Ye F, Tang C, Wang D, Zheng S. Early experience with the modificated approach of ligation of the intersphincteric fistula tract for high transsphincteric fistula. World J Surg. 2015 Apr;39(4):1059-65. doi: 10.1007/s00268-014-2888-1[↩]
112. Bastawrous A, Hawkins M, Kratz R, Menon R, Pollock D, Charbel J, Long K. Results from a novel modification to the ligation intersphincteric fistula tract. Am J Surg. 2015 May;209(5):793-8; discussion 798. doi: 10.1016/j.amjsurg.2015.01.002[↩]
113. Lehmann JP, Graf W. Efficacy of LIFT for recurrent anal fistula. Colorectal Dis. 2013 May;15(5):592-5. doi: 10.1111/codi.12104[↩]
114. Gingold DS, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn’s disease. Ann Surg. 2014 Dec;260(6):1057-61. doi: 10.1097/SLA.0000000000000479[↩]
115. Tan KK, Tan IJ, Lim FS, Koh DC, Tsang CB. The anatomy of failures following the ligation of intersphincteric tract technique for anal fistula: a review of 93 patients over 4 years. Dis Colon Rectum. 2011 Nov;54(11):1368-72. doi: 10.1097/DCR.0b013e31822bb55e[↩]
116. Jacob TJ, Perakath B, Keighley MR. Surgical intervention for anorectal fistula. Cochrane Database Syst Rev. 2010 May 12;(5):CD006319. doi: 10.1002/14651858.CD006319.pub2[↩]
117. Adams T, Yang J, Kondylis LA, Kondylis PD. Long-term outlook after successful fibrin glue ablation of cryptoglandular transsphincteric fistula-in-ano. Dis Colon Rectum. 2008 Oct;51(10):1488-90. doi: 10.1007/s10350-008-9405-2[↩][↩]
118. Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA, Sibbons P, Cohen RG. Efficacy of fibrin sealant in the management of complex anal fistula: a prospective trial. Dis Colon Rectum. 2003 Sep;46(9):1167-74. doi: 10.1007/s10350-004-6708-9[↩]
119. Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. Dis Colon Rectum. 2006 Nov;49(11):1736-40. doi: 10.1007/s10350-006-0718-8[↩]
120. Cirocchi R, Santoro A, Trastulli S, Farinella E, Di Rocco G, Vendettuali D, Giannotti D, Redler A, Coccetta M, Gullà N, Boselli C, Avenia N, Sciannameo F, Basoli A. Meta-analysis of fibrin glue versus surgery for treatment of fistula-in-ano. Ann Ital Chir. 2010 Sep-Oct;81(5):349-56.[↩]
121. Lindsey I, Smilgin-Humphreys MM, Cunningham C, Mortensen NJ, George BD. A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Dis Colon Rectum. 2002 Dec;45(12):1608-15. doi: 10.1007/s10350-004-7247-0[↩][↩]
122. Maralcan G, Başkonuş I, Aybasti N, Gökalp A. The use of fibrin glue in the treatment of fistula-in-ano: a prospective study. Surg Today. 2006;36(2):166-70. doi: 10.1007/s00595-005-3121-5[↩]
123. Sentovich SM. Fibrin glue for anal fistulas: long-term results. Dis Colon Rectum. 2003 Apr;46(4):498-502. doi: 10.1007/s10350-004-6589-y[↩]
124. Haim N, Neufeld D, Ziv Y, Tulchinsky H, Koller M, Khaikin M, Zmora O. Long-term results of fibrin glue treatment for cryptogenic perianal fistulas: a multicenter study. Dis Colon Rectum. 2011 Oct;54(10):1279-83. doi: 10.1097/DCR.0b013e318223c894[↩]
125. de Oca J, Millán M, Jiménez A, Golda T, Biondo S. Long-term results of surgery plus fibrin sealant for anal fistula. Colorectal Dis. 2012 Jan;14(1):e12-5. doi: 10.1111/j.1463-1318.2011.02747.x[↩]
126. Witte ME, Klaase JM, Gerritsen JJ, Kummer EW. Fibrin glue treatment for simple and complex anal fistulas. Hepatogastroenterology. 2007 Jun;54(76):1071-3.[↩]
127. Cestaro G, De Rosa M, Gentile M. Treatment of fistula in ano with fibrin glue: preliminary results from a prospective study. Minerva Chir. 2014 Aug;69(4):225-8.[↩]
128. Yeung JM, Simpson JA, Tang SW, Armitage NC, Maxwell-Armstrong C. Fibrin glue for the treatment of fistulae in ano–a method worth sticking to? Colorectal Dis. 2010 Apr;12(4):363-6. doi: 10.1111/j.1463-1318.2009.01801.x[↩]
129. van Koperen PJ, Wind J, Bemelman WA, Slors JF. Fibrin glue and transanal rectal advancement flap for high transsphincteric perianal fistulas; is there any advantage? Int J Colorectal Dis. 2008 Jul;23(7):697-701. doi: 10.1007/s00384-008-0460-x[↩]
130. Chung W, Kazemi P, Ko D, Sun C, Brown CJ, Raval M, Phang T. Anal fistula plug and fibrin glue versus conventional treatment in repair of complex anal fistulas. Am J Surg. 2009 May;197(5):604-8. doi: 10.1016/j.amjsurg.2008.12.013[↩]
131. Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg. 2001 Nov;108(6):1713-26. doi: 10.1097/00006534-200111000-00045[↩]
132. Hammond TM, Grahn MF, Lunniss PJ. Fibrin glue in the management of anal fistulae. Colorectal Dis. 2004 Sep;6(5):308-19. doi: 10.1111/j.1463-1318.2004.00676.x[↩][↩]
133. Lara FJ, Serrano AM, Moreno JU, Carmona JH, Marquez MF, Pérez LR, del Rey Moreno A, Muñoz HO. Platelet-rich fibrin sealant as a treatment for complex perianal fistulas: a multicentre study. J Gastrointest Surg. 2015 Feb;19(2):360-8. doi: 10.1007/s11605-014-2698-7[↩]
134. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X[↩][↩][↩]
135. The Surgisis AFP anal fistula plug: report of a consensus conference. Colorectal Dis. 2008 Jan;10(1):17-20. doi: 10.1111/j.1463-1318.2007.01423.x[↩]
136. Amrani S, Zimmern A, O’Hara K, Corman ML. The Surgisis AFP anal fistula plug: a new and reasonable alternative for the treatment of anal fistula. Gastroenterol Clin Biol. 2008 Nov;32(11):946-8. doi: 10.1016/j.gcb.2008.09.003[↩]
137. Johnson EK, Gaw JU, Armstrong DN. Efficacy of anal fistula plug vs. fibrin glue in closure of anorectal fistulas. Dis Colon Rectum. 2006 Mar;49(3):371-6. doi: 10.1007/s10350-005-0288-1[↩]
138. Ortiz H, Marzo J, Ciga MA, Oteiza F, Armendáriz P, de Miguel M. Randomized clinical trial of anal fistula plug versus endorectal advancement flap for the treatment of high cryptoglandular fistula in ano. Br J Surg. 2009 Jun;96(6):608-12. doi: 10.1002/bjs.6613[↩]
139. A ba-bai-ke-re MM, Wen H, Huang HG, Chu H, Lu M, Chang ZS, Ai EH, Fan K. Randomized controlled trial of minimally invasive surgery using acellular dermal matrix for complex anorectal fistula. World J Gastroenterol. 2010 Jul 14;16(26):3279-86. doi: 10.3748/wjg.v16.i26.3279[↩]
140. Göttgens KW, Smeets RR, Stassen LP, Beets G, Breukink SO. Systematic review and meta-analysis of surgical interventions for high cryptoglandular perianal fistula. Int J Colorectal Dis. 2015 May;30(5):583-93. doi: 10.1007/s00384-014-2091-8[↩][↩]
141. Fisher OM, Raptis DA, Vetter D, Novak A, Dindo D, Hahnloser D, Clavien PA, Nocito A. An outcome and cost analysis of anal fistula plug insertion vs endorectal advancement flap for complex anal fistulae. Colorectal Dis. 2015 Jul;17(7):619-26. doi: 10.1111/codi.12888[↩]
142. Jayne DG, Scholefield J, Tolan D, Gray R, Edlin R, Hulme CT, Sutton AJ, Handley K, Hewitt CA, Kaur M, Magill L. Anal fistula plug versus surgeon’s preference for surgery for trans-sphincteric anal fistula: the FIAT RCT. Health Technol Assess. 2019 May;23(21):1-76. doi: 10.3310/hta23210[↩][↩]
143. Zubaidi A, Al-Rowais M, Teraiki T, Alobeed O, Alkhayal K, Alkubair M. Anal fistula plug for treatment of high anal fistula: MRI evidence (Abstract). Dis Colon Rectum 2015; 58: e89.[↩]
144. Slutzki S, Abramsohn R, Bogokowsky H. Carbon dioxide laser in the treatment of high anal fistula. Am J Surg. 1981 Mar;141(3):395-6. doi: 10.1016/0002-9610(81)90207-5[↩]
145. Wilhelm A. A new technique for sphincter-preserving anal fistula repair using a novel radial emitting laser probe. Tech Coloproctol. 2011 Dec;15(4):445-9. doi: 10.1007/s10151-011-0726-0[↩][↩]
146. Salim AS, Ahmed TM. KTP-Laser and fibrin glue for treatment of fistulae in ano. Saudi Med J. 2001 Nov;22(11):1022-4[↩]
147. Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D; FATT Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum. 2012 Jul;55(7):762-72. doi: 10.1097/DCR.0b013e318255364a[↩]
148. Cho YB, Park KJ, Yoon SN, Song KH, Kim DS, Jung SH, Kim M, Jeong HY, Yu CS. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015 May;4(5):532-7. doi: 10.5966/sctm.2014-0199[↩]
149. Dietz AB, Dozois EJ, Fletcher JG, Butler GW, Radel D, Lightner AL, Dave M, Friton J, Nair A, Camilleri ET, Dudakovic A, van Wijnen AJ, Faubion WA. Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn’s Disease. Gastroenterology. 2017 Jul;153(1):59-62.e2. doi: 10.1053/j.gastro.2017.04.001[↩]
150. Prosst RL, Joos AK, Ehni W, Bussen D, Herold A. Prospective pilot study of anorectal fistula closure with the OTSC Proctology. Colorectal Dis. 2015 Jan;17(1):81-6. doi: 10.1111/codi.12762[↩]
151. Mennigen R, Laukötter M, Senninger N, Rijcken E. The OTSC(®) proctology clip system for the closure of refractory anal fistulas. Tech Coloproctol. 2015 Apr;19(4):241-6. doi: 10.1007/s10151-015-1284-7[↩]
152. Dubois A, Carrier G, Pereira B, Gillet B, Faucheron JL, Pezet D, Balayssac D. Therapeutic management of complex anal fistulas by installing a nitinol closure clip: study protocol of a multicentric randomised controlled trial–FISCLOSE. BMJ Open. 2015 Dec 16;5(12):e009884. doi: 10.1136/bmjopen-2015-009884[↩]
153. Meinero P, Mori L. Video-assisted anal fistula treatment (VAAFT): a novel sphincter-saving procedure for treating complex anal fistulas. Tech Coloproctol. 2011 Dec;15(4):417-22. doi: 10.1007/s10151-011-0769-2[↩]
154. Seow-En I, Seow-Choen F, Koh PK. An experience with video-assisted anal fistula treatment (VAAFT) with new insights into the treatment of anal fistulae. Tech Coloproctol. 2016 Jun;20(6):389-393. doi: 10.1007/s10151-016-1450-6[↩]
155. Schwandner O. Video-assisted anal fistula treatment (VAAFT) combined with advancement flap repair in Crohn’s disease. Tech Coloproctol. 2013 Apr;17(2):221-5. doi: 10.1007/s10151-012-0921-7[↩]
156. Pini Prato A, Zanaboni C, Mosconi M, Mazzola C, Muller L, Meinero PC, Faticato MG, Leonelli L, Montobbio G, Disma N, Mattioli G. Preliminary results of video-assisted anal fistula treatment (VAAFT) in children. Tech Coloproctol. 2016 May;20(5):279-285. doi: 10.1007/s10151-016-1447-1[↩]
157. Lee MJ, Freer C, Adegbola S, Elkady S, Parkes M, Hart A, Fearnhead NS, Lobo AJ, Brown SR. Patients with perianal Crohn’s fistulas experience delays in accessing anti-TNF therapy due to slow recognition, diagnosis and integration of specialist services: lessons learned from three referral centres. Colorectal Dis. 2018 Sep;20(9):797-803. doi: 10.1111/codi.14102[↩][↩]
158. Strik AS, Löwenberg M, Buskens CJ, B Gecse K, I Ponsioen C, Bemelman WA, D’Haens GR. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients. Scand J Gastroenterol. 2019 Apr;54(4):453-458. doi: 10.1080/00365521.2019.1600014[↩]
159. Oliveira IS, Kilcoyne A, Price MC, Harisinghani M. MRI features of perianal fistulas: is there a difference between Crohn’s and non-Crohn’s patients? Abdom Radiol (NY). 2017 Apr;42(4):1162-1168. doi: 10.1007/s00261-016-0989-z[↩]
160. Shenoy-Bhangle A, Nimkin K, Goldner D, Bradley WF, Israel EJ, Gee MS. MRI predictors of treatment response for perianal fistulizing Crohn disease in children and young adults. Pediatr Radiol. 2014 Jan;44(1):23-9. doi: 10.1007/s00247-013-2771-5[↩]
161. Hukkinen M, Pakarinen MP, Piekkala M, Koivusalo A, Rintala R, Kolho KL. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn’s disease. J Crohns Colitis. 2014 Aug;8(8):756-62. doi: 10.1016/j.crohns.2014.01.001[↩]
162. de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn’s disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Colorectal Dis. 2016 Jul;18(7):667-75. doi: 10.1111/codi.13311[↩]
163. Jimenez M, Mandava N. Anorectal Fistula. [Updated 2021 Sep 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560657[↩]
164. Ortiz H, Marzo M, de Miguel M, Ciga MA, Oteiza F, Armendariz P. Length of follow-up after fistulotomy and fistulectomy associated with endorectal advancement flap repair for fistula in ano. Br J Surg. 2008 Apr;95(4):484-7. doi: 10.1002/bjs.6023[↩]
165. Wright M, Thorson A, Blatchford G, Shashidharan M, Beaty J, Bertelson N, Aggrawal P, Taylor L, Ternent CA. What happens after a failed LIFT for anal fistula? Am J Surg. 2017 Dec;214(6):1210-1213. doi: 10.1016/j.amjsurg.2017.08.042[↩]
166. Giarratano G, Shalaby M, Toscana C, Sileri P. Video-assisted anal fistula treatment for complex anal fistula: a long-term follow-up study. Colorectal Dis. 2020 Aug;22(8):939-944. doi: 10.1111/codi.15005[↩]